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The high gene knockdown specificity and efficiency of RNA interference (RNAi) 
provides a potentially viable avenue for the development of a new class of nucleic 
acid therapeutics for gene-based disease conditions.  However, serum instability, 
inefficient cellular trafficking and non-specific effects of small interfering RNAs 
(siRNAs), one of the functional mediators of RNAi, has necessitated the development 
of carriers to facilitate targeted cell delivery. The decline of viral vectors in human 
gene therapy as a consequence of safety issues has intensified the importance of 
non-viral vector development. Among the non-viral vectors available for siRNA 
delivery, cationic liposomes have emerged as an attractive option owing to their 
simplicity, versatility, relatively low toxicity and potential for cell-specific targeting. 
Although existing cationic lipids and liposomes traditionally used for DNA delivery 
have also been used for siRNAs, there still exists a need to develop cationic lipids 
tailored towards siRNA transfection for improved gene silencing efficiency. Among 
the cell specific targets available for RNAi therapeutics, hepatocytes expressing the 
asialoglycoprotein receptor (ASGP-R) are an ideal choice due to the large number of 
disease targets present for treatment.    
In this investigation four novel cationic liposome formulations were prepared from 
equi-molar quantities of either the cationic cholesterol derivative 3β [N-(N’,N’-
dimethylaminopropane)-carbamoyl] cholesterol (Chol-T) or 3β [N-(N’, N’, N’-
trimethylammoniumpropyl)-carbamoyl] cholesterol  iodide (Chol-Q) and DOPE, with 
and without the hepatotropic ligand, cholesteryl-β-D-galactopyranoside. 
Electrophoretic gel analysis and SYBR®green displacement assays were employed to 
determine siRNA binding and condensation efficiencies for all cationic liposomes; 
while liposome and lipoplex size measurements were made by cryoTEM. SiRNA-
lipoplex stability in serum was determined by the nuclease protection assay. Cell 
studies performed on the ASGP-R+ human hepatoma cells, HepG2 and the ASGP-R- 
embryonic kidney cells, HEK293, to determine lipoplex toxicity and transfection 




We show that the cationic liposomes formulated for this investigation were able to 
bind synthetic siRNA optimally at a positive to negative charge ratio of ± 1 : 6. In 
addition, the cationic liposomes were able to afford siRNA duplexes substantial 
protection from ribonuclease digestion in serum. From the results obtained in this 
study, it appears that the cationic liposomes are well tolerated by both the HEK293 
and HepG2 cells in vitro. More importantly, the results obtained demonstrated 
higher transfection efficiencies for the targeted lipoplexes compared with the 
untargeted controls, strongly supporting the notion that incorporation of the 
cholestryl-β-D-galactopyranoside into the liposome structure increases transfection 
efficiency to the targeted HepG2 cells in culture via ASGP receptor mediation. 
Comparative studies in the HEK293 cell line yielded low transfection effeciences in 
the order of 20%, with no significant difference being recorded between 
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Chapter One: Introduction 
 
1.1 Gene Therapy Embraces RNA interference (RNAi) 
 
Genes are the basic physical and functional units of heredity in living organisms. The 
human genome contains approximately 25 000 genes, with expression of individual 
genes requiring appropriate regulation to suit the function and environment of 
distinct cells (Sun et al., 2008). Gene abnormalities such as mutations, variations or 
deletions may result in a gene’s inability to function properly, leading to a diseased 
state (www.ornl.gov). The concept of gene therapy arose in the late 1960s and 
involves the introduction of a good copy gene to replace or compensate for one or 
more abnormal or missing genes (Emery, 2004; Tatum et al., 1967). It offered the 
prospect of treatment for a wide range of acquired or inherited human diseases such 
as cystic fibrosis, muscular dystrophy and various cancers (Emery, 2004; Lasic, 1997; 
Yadava, 2007). However, decades after its initial conception, the potential of gene 
therapy has been limited by problems of delivery, toxicity and immunogenecity 
(Yadava, 2007). Recent deaths in two gene therapy clinical trials (www.ornl.gov) 
have also contributed to its decline in favour. Researchers subsequently expanded 
the scope of gene therapy, to include gene repression molecules such as ribozymes 
and anti-sense oligonucleotides (ODNs), but these also proved disappointing (Wilson, 
2005). 
 
The discovery of a double-stranded (d/s) RNA-driven gene silencing mechanism in 
the late 1990s led to a revitalization in the field of genetic therapeutics (Castanotto 
et al., 2009; Wilson, 2005). The mechanism, termed ‘RNA interference’ (RNAi), was 
initially only viewed as a basic loss-of-function technique, but scientists soon 
recognised its potential as a viable and innovative therapeutic tool (Paroo et al., 
2007). While traditional gene therapy focused on supplying a normal copy gene, 
RNAi harnesses a natural biological process to ‘turn off’ a problematic gene through 
cleavage or repression of the associated messenger RNA (mRNA) transcript (Joshua-




successor of anti-sense techniques; and is an emerging frontier of gene therapy with 
immense therapeutic potential (Tyagi et al., 2006). Commonly referred to as ‘the 
RNAi revolution’, the discovery and development of RNAi, from basic research 
technique to therapeutic modality, has been prolific (Paroo et al., 2007).    
 




The proliferation of RNA studies coupled with the advancement of gene transfer 
technologies in the latter half of the twentieth century, heralded a new era in 
genomic science. Of great importance was the demonstration that foreign genetic 
material introduced into cells could induce potent and unexpected responses in a 
variety of organisms (Fire, 1999). The phenomenon of RNA-induced silencing was 
first documented in transgenic plants (petunias) by Jorgensen and colleagues in 1990 
(Paroo et al., 2007). They showed that the introduction of a Chalcone synthase (CHS) 
transgene resulted in a dramatic and unexpected reduction in expression of a 
homologous gene of independent transgenotes in three genetic variants (Napoli et 
al., 1990). This phenomenon was labelled co-suppression or post-transcriptional 
gene silencing (PTGS) (Jana et al., 2004). Shortly thereafter, evidence of homology-
dependent gene silencing in other organisms, such as “quelling” in fungi, emerged 
(Siomi, 2009; www.sirna.com). 
 
Nearly half a decade later, Andrew Fire and co-workers (1998) induced sequence-
specific gene silencing by the experimental introduction of RNA into the nematode 
Caenorhabditis elegans (Yigit et al., 2006). They presented a remarkable set of 
findings, namely: (i) d/s RNA proved substantially more effective at triggering 
silencing than either sense or anti-sense s/s RNA alone (Fire et al., 1998), (ii) silencing 
was specific for an mRNA homologous to the inserted d/s RNA sequence 
(DeVincenzo, 2009) and (iii) only a few molecules of injected d/s RNA were required 




action (Fire et al., 1998). This gene silencing mechanism was termed ‘RNA 
interference’ (RNAi) and the field of RNAi was initiated.  
As RNAi research gained momentum, focus subsequently shifted towards 
demonstrating its existence in mammalian cells. Initial studies were hindered by long 
d/s RNAs (>30 base pairs) activation of the interferon response pathway. It was not 
until Tuschl and colleagues (Elbashir et al., 2001 a) demonstrated or discovered that 
a smaller, synthetic duplex RNA molecule (± 21 nucleotides) inhibited specific mRNA 
targets in somatic mammalian cells (Sioud, 2004) that RNAi was catapulted from an 
‘interesting’ cellular phenomenon to so potent a technology that its discoverers 
were awarded the Nobel Prize in Medicine and Physiology a mere eight years after 
its discovery (Lee et al., 2009; www.nobelprize.org).     
                                                                                                                                 
Today, RNA interference can broadly be defined as: “a post-transcriptional gene 
silencing pathway that occurs in response to the introduction of d/s RNA into a  
cell” (Duxbury et al., 2004; Hammond, 2005). Depending on the nature of the d/s 
RNA trigger and biological system, it down-regulates homologous target genes 
through cleavage, translational repression or transcriptional inhibition of target 
mRNA (Joshua-Tor, 2004). RNAi is a diverse, evolutionarily conserved system in 
eukaryotic cells (Hutvagner, 2005) that constitutes a natural, innate defence 
mechanism against various types of foreign nucleic acids such as viruses, 
transposable elements (transposons, transgenes) and d/s RNA (Jana et al., 2004; Lee 
et al., 2009). In addition, RNAi has been implicated in proper functioning and 
development of organisms via roles in translational silencing, chromatin structure 
organisation and cellular development and differentiation (Lee et al., 2009).  
    
1.2.2 RNAi in Functional Genomics                                                                                                                                   
 
Not too long ago, scientists performed gene knock-outs using anti-sense, dominant 
negative or other knock-out techniques which proved rather ineffective (Thakur, 
2003). RNAi is generally believed to have revolutionized modern genetics by offering 
the ability to specifically and efficiently target any mRNA of interest. RNAi-based 




gene products on a genome-wide scale in higher organisms through what is known 
as ‘reverse’ genetics (www.biomedexperts.com), whereby a known gene is sought 
for an unknown function. The principle of RNAi analysis of gene function is simple i.e. 
introduction of d/s RNA or DNA encoding for d/s RNA activates the RNAi pathway so 
that properties of the affected cell(s) reflect a loss of function in the corresponding 
gene (Thakur, 2003). The ability to selectively silence specific genes without affecting 
the genome itself, combined with its ease-of-use and speed means that RNAi is one 
of the main techniques researchers employ for isolation and analysis of single gene 
function and subsequent dissection of a wide range of cellular processes 
(DeVincenzo, 2009). It is associated with a number of advantages over previous 
methods employed for gene suppression (Table 1.1) (Duxbury et al., 2004). 
 
The unbounded potential of RNAi has encouraged numerous strategies for silencing 
of virtually all protein-encoding genes in the human genome as well as various other 
plant and animal species, with studies yielding valuable information on gene function 
and pathway analysis (Aagaard et al., 2007). There are numerous examples of 
experiments in which RNAi has been utilized to (i) ascertain the function of genes 
and create large-scale high throughput screens eg. in C.elegans, Drosophila and 
several species of plants; screening of C. elegans for genes involved in obesity and 
ageing (www.functionalgenomics.org), human kinome identification of major growth 
regulating kinases in acute myeloid leukaemia cells (www.ash.confex.com); as well 
as to (ii) assess and discover what enzymes and proteins are involved in certain 
metabolic pathways eg. elucidation of the Gibberellin/ Abscisic acid signalling 


















Table 1.1: Advantages and disadvantages of various gene suppression strategies 




1.2.3 Therapeutic Implications 
 
Beyond its value for dissecting gene function, RNAi offered the prospect of target 
validation in drug development. Target validation determines whether a known 
candidate gene is responsible for a disease and whether alteration of expression of 
said gene can lead to a therapeutic effect. Drug target validation is a major obstacle 
for the bio-pharmaceutical industry (Appasani, 2005). The timeline associated with 
target validation, from discovery to completion of clinical trials, is roughly 14 years 
(Figure.1.1 a). Consequently, the financial implications are immense, approximately 
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1% resulting in a viable therapeutic. Due to its ability to specifically suppress gene 
expression, RNAi can and, to some degree, has been successfully utilized to identify 
and validate novel therapeutic targets in disease states, thus reducing the length and 






























Figure 1.1: Estimates of drug development timeline: (a) with no implementation 
of RNAi and (b) with full implementation of RNAi coupled with other technologies 
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RNAi was, moreover, a potentially useful technology for development of highly 
specific d/s RNA-based gene silencing therapeutics (ur-Rahman et al., 2009) for 
treatment of various genetic disorders, infections and other disease conditions 
(Rieschl and Zimmer, 2009). According to the central dogma of molecular biology, 
protein synthesis occurs in two steps .i.e.  
1. Transcription copies genes from d/s DNA to s/s mRNA molecules; 
2. Translation turns mRNA into functional protein form. 
Hence, there are two ways of preventing gene expression and three main time 
points at which a disease can be blocked i.e. transcriptional, post-transcriptional and 
post-translational. RNAi allows protein synthesis to be prevented at the second, 
translational/post-transcriptional step and offers the ability to control the 
development of a disease earlier on in the process, resulting in possible eradication 
of the disease state (www.bio.davidson.edu; Thakur, 2003).  
 
Conventional chemical-based drugs have, traditionally, been restricted to certain 
classes of receptors, ion-channels and enzymes. RNAi-based ‘drugs’ have expanded 
the scope of potential druggable targets since, theoretically, any disease that can be 
ameliorated through endogenous or exogenous protein knockdown is a potential 
target for RNAi therapeutics (DeVincenzo, 2009; Oh et al., 2009). RNAi offered a 
number of advantages over existing conventional and genetic therapies, namely: (i) 
RNAi utilizes cellular machinery, (ii) only requires entrance into the cytoplasm, not 
the nucleus, (iii) high potency allows for lower therapeutic dose concentrations and 
(iv) catalytic nature means that catalytic rather than stoichiometric amounts are 
required (Aagaard et al., 2007; DeVincenzo, 2009; Zhang et al., 2007).  In essence, 
RNAi silencing of disease-related mRNAs holds many advantages and may yield 
patient benefits unobtainable by other therapeutic approaches (Appasani, 2007). 
 
Scientists studied how to manipulate RNAi to silence specific genes associated with 
disease processes (Wilson, 2005), with the swift advancement from RNAi research 
discovery to clinical trials being well-documented (de Fougerolles, 2008) example:. 




mice infected with the Hepatitis B virus. This was rapidly followed by the first 
therapeutic application of RNAi, where a class of small regulatory RNAs targeted to 
the Fas mRNA resulted in protection of treated mice against liver fibrosis (Castanotto 
et al., 2009).  Clinical trials for RNAi-based treatment of human diseases commenced 
in 2004 and despite its infancy, the current list of diseases for which RNAi is being 
tested as a therapeutic modality includes: cancers, diabetes (type 2), HIV infection, 
hypocholesterolaemia, Lou Gehrig’s disease, obesity, Parkinson’s disease, respiratory 
disease, rheumatoid arthritis, wet age-related macular degeneration (Castanotto et 
al., 2009). At present, there are several RNAi clinical trials that are in progress 
worldwide (Table 1.2.) with more planned for the coming years (Castanotto et al., 
2009; Siomi, 2009).  
 
Table 1.2: List of clinical trials for RNAi-based therapeutics as of 2009 
(Adapted from Castanotto et al., 2009; Shrey et al., 2009) 
 
 





Wet age-related macular degeneration 
Diabetic macular oedema 
Phase lll 
Phase ll 
Sirna-027 Merck-Sirna Therapeutics Wet age-related macular degeneration 
 
Phase ll 
*RTP801i-14 Quark Pharmaceuticals, and Silence 
Therapeutics 
Wet age-related macular degeneration 
 
 
Phase l/ llA 
ALN-RSV01 Alynlam Pharmaceuticals Respiratory syncytial virus infection Phase ll 
MiR-122 
 
Santaris Pharma Hepatitis C viral infections Phase l 
 
NUC B1000 Nucleonics Hepatitis B Phase l 
Anti-tat/ rev 
shRNA 
City of Hope National Medical 




CALAA-01 Calando Pharmaceuticals Solid tumors Phase l 
TD101 TransDerm, and the International 







* RTP801i-14 has been licensed to Pfizer (PF-4523655) 
Other companies involved in this field, but not mentioned above, include: Avocoel, Sequitur, Cenix 






The development of RNAi drugs has become an enormous and burgeoning market 
(Grimm, 2009), with vast resources and research directed towards elucidation of all 
RNAi components and parameters. An area receiving considerable attention is the 
isolation and identification of small RNAs and the elucidation of the RNAi pathway. 
  
 
1.3 Role of small RNAs in RNAi 
 
RNA interference is part of a sophisticated network of interconnected gene control 
pathways collectively referred to as RNA silencing (Filipowicz et al., 2005; Jana et al., 
2004). An important feature uniting all RNA silencing pathways is the presence of d/s 
RNA as a trigger or intermediate molecule (Jana et al., 2004). Although the core 
protein machinery of RNA silencing is widely conserved in eukaryotes (excluding S. 
cerevisiae), different d/s RNA sources are encountered (Aravin et al., 2005). RNA 
silencing is induced by exogenous or endogenous long d/s RNAs or hairpin RNAs, 
which are processed into shorter d/s molecules, termed small, small regulatory or 
small silencing RNAs (Ameres et al., 2007; Finnegan et al., 2003; Matranga et al., 
2006).  
 
These tiny RNAs, generally 21- 30 nucleotides in length, come in many guises (Table 
1.3); however, defining aspects such as origin, structure, function and associated-
effector proteins have led to the recognition of three dominant classes: microRNAs 
(miRNAs), small (short) interfering RNAs (siRNAs) and  PIWI-interacting RNAs (piRNAs) 
(usually single-strand) (Carthew et al., 2009; Finnegan et al., 2003; Matrange et al., 
2006). Of these three classes, miRNAs and siRNAs are the principal categories of 
small RNAs that induce RNAi in a vast array of eukaryotic organisms including Homo 
sapiens (Pfeifer et al., 2010). They function as regulators of gene expression by 
altering the stability or translational efficiency of mRNAs with which they share full 
or partial sequence complementarity (Pfiefer et al., 2010; Sun et al., 2008).  miRNAs 




defending genome integrity against invasive nucleic acids (Carthew et al., 2009). 
siRNAs are the primary mediators of RNAi in mammalian cells (DeVincenzo, 2009).  
Table 1.3: Small regulatory RNAs involved in gene silencing 
(Adapted from Castanotto et al., 2009) 
 
 
*C.elegans piRNAs are 21-nucleotides. 
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endo-siRNAs: endogenous siRNAs, ra-siRNAs: repeat-associated siRNAs, ta-siRNAs: trans-acting 
siRNAs, natRNAs: natural antisense transcript siRNAs, scnRNAs: scan RNAs, tncRNAs: tiny non-coding 
RNAs. 
Furthermore, the majority of research to date into the use of RNAi as a therapeutic 
modality has focused on siRNAs as the inducer or remedial agent (de Fougerolles, 
2008). Hence greater focus shall be directed towards siRNAs in RNAi, with a brief 
introduction into the biogenesis and function of miRNAs.          
 
 1.3.1 MicroRNAs (miRNA) 
 
MicroRNAs, first discovered in 1993 by Ambros and co-workers (Lee et al., 1993), 
constitute a class of non-coding small RNAs phylogenetically widespread in plants 
and animals (Carthew et al., 2009; Cerutti, 2003; Nelson et al., 2003; Seto, 2010). 
These small RNAs, generally 20-23 nucleotides in length, are encoded within the 
eukaryotic genome, activated by transcription factors and (most) transcribed by RNA 
polymerase ll from individual miRNA genes or introns of protein-coding genes or 
polycistronic clusters encoding multiple miRNAs on a single transcript (Aravin et al., 
2005; Cullen, 2004; Seto, 2010; Sun et al., 2006). As diverse regulators of gene 
expression, miRNAs play important roles in cell growth, differentiation and 
proliferation (Pfeifer et al., 2010); and have been implicated in regulation of 
developmental timing, synaptic plasticity, insulin secretion in pancreatic islet cells 
and control of cholesterol homeostasis in the liver (Carthew et al., 2009; Sun et al., 
2008). They regulate approximately 30% of all human genes and at present more 
than 700 human miRNA sequences have been identified (Pfeifer et al., 2010, Seto, 
2010).  
 
miRNAs are generated from long stem-loop primary transcripts termed pri-miRNAs 
that are then processed within the nucleus by Drosha enzyme to yield 70 to 100 
nucleotide precursor miRNAs (pre-miRNAs) (Figure.1.2 a). Exportin-5 then transports 
these pre-miRNAs into the cytoplasm where they undergo further processing by the 




and 2 nucleotide 3’ overhangs (Figure.1.2 b) (Cullen, 2004; Matrange et al., 2007; 












 Figure 1.2:  (a) pre-miRNA hairpin structure (b) mature miRNA;     : anti-sense strand 
and         : sense strand (Adapted from Kawamata et al., 2010). 
 
miRNAs mainly interact with target mRNAs via “seed sites” between nucleotide  base 
pairs 2 and 7/8 of the miRNA molecule which corresponds to sequences within the 3’ 
untranslated region (UTR) of the target transcript (Matrange et al., 2007; Pfeifer et 
al., 2010; Shrey et al., 2009). Inhibition of target RNAs is achieved through one of 
two mechanisms as determined by the degree of complementarity between miRNAs 
and target mRNAs (Sun et al., 2008). Full or high complementarity is associated with 
mRNA degradation -most common in plants (Meister et al., 2004), while imperfect or 
partial complementarity, with translational repression, characteristic of animal 
miRNAs (Cullen, 2004; Pfeifer et al., 2010).       
 
1.3.2 small interfering RNAs (siRNAs)                                                                                           
   
siRNAs, often referred to as the function mediators, effectors or triggers of RNAi 
(Oliveira et al., 2006; Watts et al., 2008), were first detected in 1999 by Hamilton et 
al during virus- and transgene-induced  silencing experiments in plants (Finnegan et 
al., 2003; Pfeifer et al., 2010). These d/s nucleic acids are generally 19 to 25 







  HO 
     P 
  OH 
 P 
Seed Region 
weight of approximately 13 to 15 kilodaltons (Hutvagner et al., 2005; Oliveira et al., 
2006; Zhang et al., 2007; Wadhwa et al., 2004).  siRNAs are generated from an ATP-
driven (in certain species), Dicer-mediated cleavage of long d/s RNA precursors, 
yielding short duplexes with 5’-phosphate and 3’-hydroxyl terminal groups, and 
symmetrical 2 nucleotide 3’ overhangs. (Figure.1.3) (Hutvagner et al., 2005; Nguyen 







Figure 1.3:  Structure of siRNA; siRNA is composed of two strands- a 21 bp region of 
duplex, with dinucleotide overhangs (   ) on the 3’ end of each strand, 5’-phoshates 
and 3’-hydroxy termini. The site at which the mRNA target is cleaved is indicated by 
an arrow.      : anti-sense strand and      :sense strand (Modified from Chen et al., 
2010; DeVincenzo, 2007; Shan, 2009). 
 
The d/s precursors are primarily exogenous in origin, with endogenous sources being 
rare (Aravin et al., 2005; Carthew et al., 2009). siRNA sources include: viral RNAs, 
hairpin RNAs, repeat-associated transcripts (centromeres, transposons), convergent 
transcripts and other sense/anti-sense pairs, gene/pseudogene duplexes, transgene 
transcripts, trans-acting RNAs and environmentally, experimentally or clinically 
introduced d/s RNAs ( Carthew et al., 2009). Eukaryotes synthesize long d/s RNAs via 
2 distinct mechanisms i.e. (i) bi-directional transcription of inverted transgene/ 
transposon repeats, and (ii) read-through transcription of convergent promoters. 
Primary or aberrant transcripts can also be utilised by organisms encoding for RNA-
dependent RNA polymerases (RdRP) (Hutvagner, 2005). The length of the d/s 
precursor may vary, depending on species (Hutvagner et al., 2005) for example, in 
C.elegans and Drosophila, they may be greater than 500 base pairs (bps).  Exogenous 
d/s RNA precursors longer than 30 nts induce an interferon (IFN) response in 
mammalian cells (Duxbury et al., 2003; Pfeifer et al., 2010). Therefore, siRNAs 




through chemical synthesis, enzymatic cleavage or expression systems/cassettes to 
reduce host cell immune recognition of inserted d/s RNAs (These methods of siRNA 
production shall be addressed in greater detail later on in this chapter) (Leung et al., 
2005; Pfeifer et al., 2010).        
siRNAs function in defence, protecting the host organism against foreign nucleic 
acids (Finnegan et al., 2003). They have been widely utilized in mammalian cells for 
elucidation of gene function, cellular pathway analysis, identification of disease-
related genes and, most importantly, as potential therapeutic agents (Leung et al., 
2005). siRNAs, once generated, are assembled asymmetrically into a multi-
component complex, in which they serve as a sequence recognition element, 
directing homology-dependent cleavage of target mRNA in the region of 
complementarity (Aagaard et al., 2007; Boese et al., 2003; Moss, 2001; Yadava, 
2007). In contrast to miRNAs, siRNAs are perfectly complementary to target mRNAs 
(Moss, 2001; Pfeifer et al., 2010); they are complementary to both the sense and 
anti-sense strands of the targeted mRNA and have a distinct chemical polarity that is 
essential for their function (Appasani, 2005). The characteristic nucleotide 3’ 
overhangs aid in recognition by the multi-component complex (Aagaard et al., 2007); 
while the thermodynamically less stable anti-sense strand is preferentially loaded at 
the 5’ terminus (Shrey et al., 2009; Yadava, 2007). Base composition at the 5’ end 




















1.4 The RNA interference Pathway 
 
 The RNAi mechanism (Figure.1.4) is a multi-step process that can be divided into 
two phases: (i) initiation phase and (ii) effector phase. During the initiation phase, 
long d/s RNA or precursor miRNA are cleaved, by an RNase lll endonuclease enzyme, 
Dicer, into 19-25 nt siRNAs or mature miRNAs (Duxbury et al., 2004; Shrey et al., 
2009; Yadava, 2007). Dicer (Figure.1.5 a) is a ~200 kDa protein generally containing 
an N-terminal ATPase/RNA helicase, followed by a domain of unknown function 
(DUF 283), a Piwi/Argonaute/Zwille (PAZ) domain, two RNase lll domains and a C-
terminal RNA binding domain (RBD) (Filipowicz et al, 2005; Patel et al, 2006; 
Wadhwa et al., 2004; Van den Berg et al., 2008). Some organisms encode for a single 
Dicer gene (eg. vertebrates), whilst others have more than one Dicer homologue (eg. 
Drosophila) (Filipowicz et al., 2005; Van den Berg et al., 2008).    
        
Dicer functions as a monomer with a single processing centre (Filipowicz et al., 2005). 
First, the PAZ domain engages the d/s RNA substrate at the 3’ end (recognition of ~2 
nucleotide overhang), with the substrate extending approximately 2 helical turns 
along the protein surface prior to reaching a cleft created by intramolecular 
dimerization of the two RNase lll domains (Figure.1.5 b). This is the processing centre 
which contains two independent catalytic sites, each cutting one RNA strand 
simultaneously and asymmetrically, generating appropriately sized siRNAs or 
miRNAs with characteristic 3’ dinucleotide overhangs and 5’ phosphates (Carthew et 
al., 2009; Filipowicz et al., 2005; Patel et al., 2006). The distance between the PAZ 
domain and the processing centre appears to dictate the size of the generated 
duplex, differing among species (Carthew et al., 2009). In some species, Dicer may 
function as part of a heterodimeric complex with a TAR-RNA binding protein (TRBP) 























Figure 1.4: The RNAi pathway, showing both miRNA-mediated mRNA repression and 














Figure 1.5.:  (a) shows domain arrangement of most Dicer enzymes (top) and Dicer 
structure with long d/s RNA (blue), active-site metal ions (purple) and a ‘ruler’ helix 
(red). (b) is an illustration of Dicer binding long d/s RNA or pre-miRNA (Modified 
from Carthew et al., 2009; Hammond, 2005). 
 
The effector phase commences when Dicer transfers the d/s RNA substrate to the 
multi-protein RNA-induced Silencing Complex (RISC) (Duxbury et al., 2004; Shrey et 
al., 2009; Tseng et al, 2009). RISC is a 160 to 500 kilodalton (Ameres et al., 2007; 
Yadava, 2007) complex containing Argonaute (Ago) proteins, a DEAD-box helicase 
(Gemin-3),  a protein of unknown function (Gemin-4), Dicer and other as yet 
undetermined proteins (Wadhwa et al., 2004; Watts et al., 2008; Yadava, 2007). The 
Ago proteins are regarded as the core of RISC (Filipowicz et al., 2005; Kawamata et 
al., 2010; Tseng et al., 2009), having 4 homologs (Ago1, 2, 3 and 4) in humans- of 
which only Ago2 demonstrates catalytic cleavage activity (Tseng et al., 2009), and a 
structure composed of an N-terminal PAZ domain (± 150 residues) linked by a region 
of variable length (MID) to a C-terminal Piwi domain (± 400 residues) (Parker et al., 
2006; Tseng et al., 2009). These 3 domains form a crescent-shaped base, with the 






et al., 2005). The less thermodynamically stable 5’ end is then chosen as the guide 
strand (i.e. anti-sense strand), the duplex is unwound and the passenger strand (i.e. 
sense strand) is cleaved (Kawamata et al., 2010; Tseng et al., 2009). The process via 
which unwinding (ATP-dependent) and passenger-strand degradation occurs has not 
yet been fully elucidated, although numerous theoretical models (eg. the helicase 
model) have been proposed (Hutvagner, 2005; Kawamata et al., 2010).  
 
The now functional RISC (denoted by RISC*) containing the guide-strand hybridizes 
to its complementary target mRNA via Watson-Crick intermolecular base pairing 
(Aagaard et al., 2007; Sashital et al., 2009). The RNase H-like Piwi domain of Ago, 
containing the conserved D(Asp)-D(Asp)-H(His) (DDH) motif, hydrolyzes the 
phosphodiester bonds between the target nucleotides base paired to guide-strand 
residues 10 and 11, relative to the 5’ end of the siRNA (Aagaard et al., 2007; Carthew 
et al., 2009; Filipowicz et al., 2005; Siomi, 2009). The resulting 5’ and 3’ fragments 
are released from RISC* and attacked by cellular exonucleases, completing the 
degradation process (Carthew et al., 2009; Sioud, 2004). RISC* is now free to target 
other complementary mRNAs, allowing for multiple-rounds of RNA cleavage 
(Carthew et al., 2009; Filipowicz et al., 2005). In the case of mismatches between the 
siRNA and target mRNA, the siRNA behaves like miRNA in RNAi, with the ‘seed 
region’ of the anti-sense strand base pairing precisely with the target while 
mismatches are seen in other regions, leading to arrest in translation and 
sequestration of target mRNA in cytosolic P-bodies. This might eventually result in 
de-capping and degradation of the mRNA (Juliano et al., 2008). The above 
mechanism may demonstrate slight variance amongst the species, but it is a good 
representation of the pathway as observed in most eukaryotic systems, including 
humans. Although RNAi can be activated by miRNAs and siRNAs, the involvement of 
the nucleus in miRNA biosynthesis has meant that developers of human therapeutics 
have largely steered clear of it, opting instead to utilize the siRNA-mediated RNAi 











1.5 siRNA Therapeutics 
 
1.5.1 Promise and Limitations of siRNAs as Remedial Agents 
 
For therapeutic purposes, siRNAs hold several distinct advantages over other gene-
based therapeutic agents or traditional pharmaceutical drugs currently on the 
market (Sato et al., 2008). These include the fact that siRNAs are naturally utilized by 
cells for regulation of gene expression, making them a low toxicity or non-toxic risk 
(www.biologykenyon.edu; Sato et al., 2007). The fact that they are part of a natural 
process also means that these molecules are highly effective and reliable at gene 
silencing (www.biology.kenyon.edu; Grimm, 2009; Ma et al., 2005). siRNAs can be 
produced synthetically, they make use of a catalytic mechanism, operate in the 
cytoplasm, demonstrate high target selectivity, mediate PTGS in a wide variety of 
primary cells and demonstrate greater resistance to nuclease degradation than their 
anti-sense counter-parts (Sato et al., 2007; Zhang et al., 2007). The above, combined 
with their ease of design and synthesis, low production cost (compared with other 
therapies), consistent and predictable manner and ability to enter the RNAi pathway 
late, so as to minimize interference with endogenous miRNA gene regulation, makes 
siRNAs particularly attractive therapeutic agents (De Fougerolles, 2008; Leung et al., 
2005; Sato et al., 2007).   
 
Despite this immense attractiveness, siRNA duplexes are not optimal drug-like 
molecules (Watts et al., 2008). Their physiochemical properties, such as anionic 
nature, high molecular weight and hydrophilicity mean that siRNAs do not easily 
cross lipophilic cell membranes (Kim et al., 2010; Oliveira et al., 2007; Wang et al., 
2009) and are rapidly eliminated by the renal glomeruli (Sato et al., 2008; Watts et 
al., 2008). They are highly vulnerable to serum exo- and endonucleases, leading to a 




off-target effects and have limited tissue specificity/distribution (Nguyen et al., 2008; 
Watts et al., 2008). The inherent promise of siRNAs as therapeutic agents out-weighs 
their disadvantages, but these problems need to be addressed so as to produce a 
practical and efficient means of treating human diseases (Minchin et al., 1999). The 
development of new approaches and adaptation of previously utilized gene delivery 
strategies, for siRNA therapeutics shall be discussed in detail. 
 
  
1.6 Strategies for siRNA Design and Manufacture  
 
The first set of empirical rules for siRNA design, based on studies performed on 
Drosophila, was compiled by Tuschl et al (Elbashir et al., 2001b) and basically stated: 
 
1) siRNA duplexes should contain 21 nucleotide base pairs with 3’ dinucleotide 
dTdT overhangs; 
2) Nucleotides 1-19 of the sense siRNA strand should match positions 3-21 of 
the 23-nucleotide target mRNA; 
3) Target sequence should ideally contain a 50% GC content; 
4) Targeted region is selected from a given cDNA sequence, 50 to 100 
nucleotides downstream of the start codon; 
5) The target motif is selected in the following order of preference: i) 
NAR(N17)YNN, where N= is any nucleotide, R= purine and Y=pyrimidine; ii) 
AA(N19)TT; iii) NA(N21); 
6) Selected siRNA sequences should be aligned against EST libraries to ensure 
target of a single gene.    
 
Exceptions to the above were reported by Ding et al. (2005) (Appasani, 2007; 
www.sfold.wadsworth.org) and advances in our understanding of siRNAs and RNAi 
helped refine these rules. Today, general guidelines for siRNA design include the 
avoidance of intron regions, repeats, stretches of 4 or more nucleotides such as 
AAAA (homopolymime), and GC content <30% or >60%. It is also advisable to 




can also be utilized (www.protocol-online.org). There are currently multiple software 
and internet search programs available to researchers for the selection of optimal 
siRNA sequences (Shan, 2009). An example of an siRNA sequence can be seen in 
Figure 1.6. The careful selection of sequences is required for minimization of off-





N2(G/C)N8(A/T)N8(A/T)N2   
 
    
    (mRNA)       5´…TAAGCACGAGTGGAATAACCTCATTTTGGT… 3´ 
     (sense)                     5´ CGAGUGGAAUAACCUCAUUUU 3´ 
 
    (anti-sense)             3´ GUGCUCACCUUAUUGGAGUAA 5´ 
 
 
Figure 1.6: An example of target mRNA and corresponding siRNAs. Presented 
sequences are illustrative and do not agree with any mRNA and/or published siRNAs 
(Pei and Tuschl, 2006). 
 
Scientists developed various approaches (Figure 1.7) for the production of synthetic 
siRNAs. The two main strategies currently employed are: (i) chemically synthesized 
or in vitro transcribed siRNAs and (ii) viral/plasmid vectors containing cassettes 
encoding short hairpin RNAs (shRNAs) transcribed with U6- or H1-like promoters and 
processed into siRNA by Dicer (Myers et al., 2005; Shan, 2009; Wadhwa et al., 2004). 
shRNA cassettes can be integrated into the host genome or stably retained  as extra-
chromosomal copies enabling long-term, persistent therapeutic effect (Lee et al., 
2009); however, concerns over access to the nucleus and saturation of endogenous 
miRNA pathways, have most impending RNAi therapeutics utilizing direct 
introduction of chemically synthesized siRNAs instead (Castanotto et al., 2009). 
Although the cost of chemical synthesis is high and the effects are transient (< 2 




chemical modifications mean that these molecules are favoured for induction of 







Figure 1.7: Strategies for siRNA production. siRNAs can be either generated in vitro 
and then introduced into cells (A,B or F), or produced in vivo from transcription  of a 
DNA template (C, D or E). C and E: siRNAs derived from hairpin precursors (Appasani, 
2005). 
Chemical modifications (Figure 1.8.), such as incorporation of a modified sugar 
moiety (eg. 2’-O-methylation of the ribose), modifications to the duplex structure, 
overhangs and termini (eg. deoxy units), linkage modifications (eg. phosphorothioate 
bonds) and base modifications have been shown to improve siRNA stability in serum, 
increase potency, reduce immunostimulatory properties and diminish hybridization-
dependent off-target effects (Watts et al., 2008; Yadava, 2007). Conjugation to 
molecules, such as cholesterol have also aided in improving the overall 
pharmacokinetics of siRNAs for medical application (Yadava, 2007). Although 
chemical modifications have been shown to increase stability of siRNAs in serum, 
they fail to solve both the problem of poor pharmacokinetics and the lack of tissue 
specificity associated with these molecules (Cardoso et al., 2008). Hence 
development of effective delivery systems or vectors is an imperative and on-going 




                           









Figure 1.8: Examples of different types of chemical modifications applied in siRNA 
synthesis, where A: sugar modifications (2’-O-alkyl and other 2’ modification), B: 
structural modifications (sisiRNA: small internally segmented interfering RNA), C: 
internucleotide linkages (s=sulphur, BH3=borane), and D: nucleobase modifications 
(R= ribose phosphate backbone) (Modified from Watts et al., 2008). 
1.7 siRNA Delivery Systems and Vectors 
 
The anionic nature and large size of nucleic acids necessitates involvement of 
delivery systems or vehicles for therapeutics (Lasic, 1997). A delivery vector refers to 
a ‘bearer’ or ‘carrier’, and in the context of gene delivery, is a means of transporting 
therapeutic nucleic acids from the site of administration to the site of action (Mēvel 
et al., 2009).  Delivery could be local (target organ), systemic (bloodstream) or 
targeted (systemic designed for intended target) (Seto, 2010). An ideal vector should 
be easy to produce and reproducible, biodegradable, non-toxic, non-immunogenic, 
stable (storage and administration), demonstrate efficient gene expression and 
possess cell-specific targeting ability (Guo et al., 2010; Huang et al., 1999; Li and Ma, 
2001; Reischl et al., 2008). Most vectors can be classified into 1 of 2 groups, either: 
viral or non-viral. Both have been utilized for siRNA or shRNA delivery and have 
intrinsic advantages and disadvantages (Mēvel et al., 2009).  
  
 
1.7.1 Viral Vectors 
 
Viruses are naturally evolved vehicles which efficiently transfer their genes into host 
cells, making them attractive delivery vectors for transport of therapeutic genes into 
humans (Huang et al., 1999; Walther, 2000; Yadava, 2007). They can be genetically 
engineered to be less or non-virulent, with all or part of their viral sequence replaced 
by therapeutic genes (Li and Ma, 2001; Singh et al., 2009).  Viral vectors are highly 
efficient gene delivery vehicles, owing to their superior cell adhesion, membrane 
translocation and transcriptional and translational abilities (Cristiano, 1998; Yadava, 
2007). In addition, their ability to transduce both dividing and non-dividing cells, 
stably integrate exogenous DNA or RNA into the host genome- yielding prolonged 
expression of therapeutic genes, low dose requirement, amenability to pseudotyping 




numerous gene therapy /RNAi experiments and clinical trials (Singh et al., 2006; 
Singh et al., 2009).    
  
Adenoviruses, Adeno-Associated viruses (AAV), Lentiviruses and Retroviruses are the 
most widely utilized viral vectors in RNAi therapeutics (Lee et al., 2009; Singh et al., 
2009). Each virus type has its advantages and disadvantages (Table 1.4.). Viral 
delivery in RNAi is usually associated with shRNAs as most viruses are unable to carry 
synthetic chemical analogs (siRNAs) (Grimm, 2009; Oliveira et al., 2006; Yadava, 
2007). Adenoviruses are icosahedral, non-enveloped DNA viruses (Huang et al., 1999; 
Majhen and Ambriovic-Ristov, 2006), with the ability to transduce dividing and non-
dividing cells. However, low packaging capacity (approximately 7.5 kb), no genome 
integration and immunogenicity have hindered their application (Singh et al., 2009). 
AAV are non-pathogenic viruses belonging to the Parvoviridae class. They are 
regarded as the safest viral vector due to lack of associated malignancy and immune 
response (Huang et al., 1999; Singh et al., 2009). They have been extensively utilized 
in shRNA delivery. In 2007 Li et al engineered AAV-1, -2 and -5 serotypes to express 
shRNA against Hec1 (cancer-associated gene) in central nervous system (CNS) tumor 
cells. Doege et al used AAV vectors for expression of shRNA against the hepatic fatty 
acid transport protein-5 (FATP-5). Both investigations demonstrated efficient and 
persistent target gene knockdown (Grimm, 2009). 
 
 Lentiviral vectors have also been successfully employed for shRNA delivery in 
various mammalian systems. Carlson et al (2008) delivered a Smad3-target shRNA 
for satellite cell regeneration (Singh et al., 2009); while An et al knocked down 
rhesus-CCRS (HIV chemokine receptor) in non-human primates (Nyugen et al., 2008). 
Down regulation of Ras oncogene in mice have also been reported (Brummelkamp et 
al., 2002). The most widely used lentiviral vectors are HIV-based. Major safety 
concerns are associated with this type of vector (Singh et al., 2009). Retroviruses 
have been used to express shRNAs by pol ll/lll vectors, but random integration has 
impeded application (Singh et al., 2009). Herpes viruses, baculoviruses and 
virosomes (empty influenza envelops) are also being investigated as potential 






Table 1.4: Advantages and disadvantages of different types of viruses as nucleic acid 














Transfects  dividing and non-
dividing cells 
High transfection efficiency (in 
vitro &  in vivo) 
 Extensive clinical use 
Transgene size limit of 7.5 kb 
Immunogenicity 
No genome integration i.e. 
short-lived gene expression 





Wide tissue range 
Transfects dividing and non-
dividing cells 
No associated immune response 
or malignancy 
High transfection efficiency 
Transgene size limit of 4.5 kb 
Random genome integration i.e. 
mutagenesis 
Little clinical experience 




Transfects dividing and non-
dividing cells 
Convenient to manufacture  
 




Host genome integration i.e. long-
lasting gene expression 
Low immunogenicity 
High transfection efficiency (ex 
vivo) 
Extensive clinical use 
Transfects dividing cells only 
Transgene size limit of 8 kb 
Random genome integration  i.e. 
mutagenesis 
Restricted host range 






Despite the success and reduced risks associated with new generation viral vectors 
(Castanotto et al., 2009;  Nyugen et al., 2008), possible immunogenicity, toxicity, 
carcinogenicity, insertional mutagenesis, aberrant gene induction and infection due 
to pathogenic reversion (Chaudhuri, 2002; Lasic, 1997; Walther, 2000) are still major 
limitations to their therapeutic application. These safety concerns have not yet been 
resolved for human application (Takahashi et al., 2009).  
 
1.7.2 Non-Viral Systems and Vectors 
 
Non-viral delivery systems are attractive alternatives to their viral counter-parts. 
Ease of preparation, low cost, low toxicity, reduced risk of immunogenicity, high 
stability, flexible nucleic acid loading capacity, amenability to modifications and 
ability for cell-specific targeting are among the many reasons why they are regarded 
as more attractive vectors for clinical application (Han et al., 2008; Huang et al., 1999; 
Li et al., 2008; Mēvel et al., 2010; Oliveira et al., 2006; Zhang et al., 2010). They 
encompass a wide array of molecules and techniques, broadly divided into two 
categories: naked nucleic acid delivery by a physical method or 
complexation/precipitation with a carrier molecule (Nishikawa et al., 2001). 
Generally, chemical or colloidal in nature (Lasic, 1997; Singh, 1998), there are 3 
major classes of non-viral delivery vectors: synthetic polymers, 
biodegradable/natural polymers and lipids (Rao et al., 2009).  Low transfection 
efficiency and transient gene expression were features of early non-viral delivery 
systems, however recent advancements in vector technology have yielded molecules 
and techniques with transfection efficiencies comparable with those of viruses 
(Yadava, 2007).  Currently, various siRNA delivery vectors are being developed and 
investigated, including polymers, peptides and liposomes (Kim et al., 2010). Some 
non-viral delivery systems shall be discussed below.     
 





Electroporation, first used for gene delivery by Zimmerman et al. (1976), involves the 
application of short bursts of high voltage electric pulses to cells, inducing transient 
membrane breakdown and allowing entrance of nucleic acids into the cytoplasm 
(Nishikawa et al., 2001, Singh, 1998). It has been successfully employed for siRNA 
delivery, example: local delivery into the hippocampal region demonstrating efficient 
knockdown of the COX1 gene and reduced levels of metabotropic glutamate 
receptor-2 (mGluR2) in the brain (Akaneya et al., 2005; Singh et al., 2009). The 
simplicity and reproducibility of electroporation have been overshadowed by its lack 
of in vivo applicability i.e. cell damage at pulse-applied sites and inconsistent 
expression in assorted tissue-types makes large-scale implementation difficult 
(Nishikawa et al., 2001; Oh et al., 2009; Singh, 1998).  
 
Nucleofection is an advancement of electroporation. It employs less harmful electric 
pulses and specialized solutions for cell-specific delivery (Gresch et al., 2004). 
Although effective, Electroporation and Nucleofection are fairly toxic to several cell 
types (Lee et al., 2009).  
 
Hydrodynamic injection technique involves intravascular injection of a large amount 
of physiological buffer containing naked siRNA. It was the first technique used to 
demonstrate siRNA induced RNAi in mammalian cells.  Advantages include relative 
simplicity, low cost, relatively high efficacy and low dose requirement. Transient 
toxicity, rapid nucleic acid degradation and the need for organ-specific vasculature 
are the three major limitations for therapeutics (Lewis and Wolff, 2005; Lewis and 
Wolff, 2007).  
 
1.7.2.2 Polymers and Peptides 
 
Polymers utilized for gene delivery can be either natural or synthetic and are 
generally cationic in nature. The complexes formed between nucleic acids and 
cationic polymers, via electrostatic interaction, are referred to as ‘polyplexes’ 
(Felgner et al., 1997; Huang et al., 1999). Examples of polymers used in in vivo siRNA 




polyethyleneimine (PEI) and cyclodextrin (De Fougerolles, 2008; Singh et al, 2009; 
Zhang et al., 2007). Although very efficient, toxicity (example: PEI) has been a 
deterrent for delivery purposes (Yadava, 2007).  
 
In general, cationic proteins and peptides are used to form complexes with anionic 
nucleic acids (De Fougerolles, 2008). Membrane penetrating peptides (MPPs), 
characterised by presence of highly basic amino acids such as arginine and lysine, 
have been extensively investigated as siRNA delivery vectors. Low cost, ease of 
preparation and non-toxic effects are advantages (De Fougerolles, 2008; Hwang et 
al., 2008). Observed immunogenicity and tendency of positively charged MPPs to 




Liposomes are vesicular colloidal particles composed of self-assembled amphiphilic 
molecules in an aqueous environment (Lasic, 1997). They were first described by 
Bangham et al in 1965; and owing to their resemblance to biological membranes, 
were originally used to model membrane systems in molecular biology studies. 
Recognition of their carrier potential resulted in their use in the fields of drug and 
gene delivery (Singh, 1998; Huang et al., 1999). Liposomes consist of one or more 
concentric lipid bilayers alternating with aqueous compartments, within which a 
variety of lipid- or water-soluble substances can be entrapped (Bangham et al.,1972; 
Singh et al., 2006). Although composition depends largely on the goals of the 
experiment, liposomes are generally comprised of phospholipids, charged 
amphiphiles and sterols (Kinsky, 1974). There are four different types of liposomes, 
defined on the basis of functionality (Figure 1.9.) (Huang et al., 1999; Lasic, 1997). 
Conventional or classical liposomes were the first to be synthesized. They were 
composed of neutral or anionic lipids such as phosphatidylethanolamine (zwitterion) 
or phosphatidylserine (anionic). They encapsulated nucleic acid material within their 
aqueous compartments. However, variable encapsulation efficiencies, relatively 




deemed inefficient for gene delivery, particularly for in vivo application (Szelei and 




Figure 1.9: Illustration of the four different classes of liposomes (conventional, 
cationic, targeted and stealth) as defined by functionality (Lasic, 1997); where (●) 
refers to positively charged moieties, (Ү) targeting ligands and ( ) polymer coatings 
(Lasic, 1997). 
 
The introduction of cationic lipids into liposome preparation allowed for the first 
truly efficient liposomal gene delivery system (to be discussed) (Lasic, 1997). 
Targeted and stealth liposomes are variations of conventional and cationic liposomes. 
Targeted liposomes contain targeting moieties, such as antibodies, lectins, or 
oligosaccharides, directed towards cognate receptors/sites on specific cells and 
tissues. They addressed a major limitation of gene delivery systems i.e. lack of cell 
specificity. Stealth liposomes carry a polymer coating that increases their circulation 
time by preventing liposomal cell adhesion and protein opsinization (Lasic, 1997; 
Singh et al., 2006). Liposomes exhibit many of the characteristics required of an ideal 
delivery vector including their ease of production, amenability to scale-up 
production, relatively low cost and safety (Huang et al., 1999; Lasic, 1997; Percot et 





Liposomal gene transfer can occur through one of four mechanisms (figure 1.10.), 
namely: (i) Adsorption with extracellular release, (ii) Adsorption with lipid exchange, 
(iii) Endocytosis, and (iv) fusion of vesicle with cell wall. The mechanism used is 
determined by liposome characteristics, such as size, charge, composition, targeting 
ligand; and cell type (Torchilin, 2003). It was originally hypothesized that liposomal 
gene transfer occurred primarily as a result of direct fusion between the plasma 
membrane and the nucleic acid-liposome complex  (termed ‘lipoplex’) (Felgner et al., 
1987), but that was later disputed (Zhou et al., 1994). Rather, it is mainly through the 
process of endocytosis that lipoplexes entered the cell (Pinnaduage et al., 1989). 
Escape of lipoplexes from the endosome is considered a critical factor for efficient 





Figure 1.10: The four mechanisms of liposome-cell interaction by which liposomes 
deliver their cargo (Modified from Torchilin, 2003).  
 
In one mechanism proposed by Xu and Szoka, cationic lipids may form ion-pairs with 
the anionic lipids of the endosome resulting in destabilization of the endosome 
membrane by exclusion of surface bound water (Tseng et al., 2009).  The ‘proton 
sponge effect’ is another very effective method via which siRNA escapes endosomal 
degradation. Here, the buffering capacity of molecules contained within the 




liposome can cause the influx of Cl-  molecules resulting in swelling and rupture of 




Figure 1.11: Endosomal escape in lipoplex-mediated siRNA delivery (Tseng et al, 





sponge effect; D: Free highly positive charged molecules; E: Ruptured endosome and 
cytoplasmic de-assemblage of siRNA; and F: SiRNA de-assemblage in endosome prior 
to release from ‘holes’ in ruptured endosome (Tseng et al., 2009). 
1.7.2.4 Cationic Liposomes 
 
The apparent high toxicity associated with cationic lipids limited their exploration 
and use in early liposomal and gene delivery research (Lasic, 1997). It was only in 
1987 when Felgner et al synthesized a mono-cationic lipid, N-[1-(2,3-dioleyloxy) 
propyl]-N,N,N-trimethylammonium chloride (DOTMA), that the first evidence of 
their efficient transfection ability with low toxicity was demonstrated (Bhattacharya 
et al., 1998; Lasic, 1997; Felgner et al., 1987; Singh, 1998). This resulted in the 
development and synthesis of a plethora of other cationic lipids for use in gene 
delivery (Figure 1.12.) (Lasic, 1997; Singh, 1998).  
 
 
      
 
 
               
 
 
Figure 1.12: Structures of four common cationic lipids, A: 3β-[N-(N’,N’-
dimethylaminoethane)- carbamoyl] cholesterol hydrochoride (DC-Chol); B: 1,2-
dioleoyl-3-trimethylammoniumpropane (DOTAP) ; C: DOTMA and D: O,O’-









Cationic liposomes are generally composed of a cationic lipid in combination with a 
neutral co-lipid (Lasic, 1997; Reischl et al., 2008). Commonly used co-lipids include 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-Dioleolyphophatidyl-
ethanolamine (Lasic, 1997; Guo et al., 2010). Cationic liposomes carry a net positive 
charge over their surface allowing for spontaneous complexation with anionic 
nucleic acids such as siRNAs, via electrostatic interaction between the negatively 
charged phosphate backbone of the nucleic acid and the positively charged amine 
head group of the cationic lipid (Behr, 1986; Reischl et al., 2008). They offer a 
number of advantages as gene delivery vectors, including ease of preparation, 
limitless nucleic acid loading capacity, relatively high transfection ability due to 
increased binding affinity with negatively charged cell membranes, and significantly 
reduce therapeutic dose concentrations (Bhattacharya et al., 1998; Guo et al., 2010; 
Rao, 2009; Rhinn et al., 2009). 
 
Cationic liposome-mediated siRNA delivery has been successfully utilized by several 
groups for in vitro and in vivo gene knockdown (Guo et al., 2010). It was 
demonstrated that a cationic lipid, 2-(3-[bis-(3-amino-propyl)-amino]-propylamino)-
N-ditetradecylcarbomoyl-thyl-acetamide (RPR209120), combined with DOPE, 
efficiently delivered siRNAs to mammalian cells in culture, silencing tumor necrosis 
factor α (TNF-α) in collagen induced arthritis (Khoury et al., 2006; Zhang et al., 2007). 
In 2006, Santel and collegues synthesized a stealth cationic liposome composed of 
the cationic lipid, β-L-arginyl-2,3-L-diaminopropionicacid-N-palmityl-N-oleylamide 
trihydrochloride (AtuFECT01) in combination with a fusogenic lipid (1,2-diphytanoyl-
sn-glycero-3-phosphoethanolamine) and PEG. It was used to deliver siRNA to the 
vascular endothelium of mice, targeting CD31 and Tie2 genes. Reduction of target 
protein levels were observed in the vascular endothelium of the heart, lung and liver 
(Santel et al., 2006; Oh et al., 2009). Recently, a cationic lipid (DODAG 8) synthesized 
and complexed to anti-Hepatitis B Virus (HBV) siRNAs, demonstrated efficient 






Although cationic lipid/liposome based systems have demonstrated their potential 
as siRNA delivery vectors, several hurdles remain for therapeutic application (Oh et 
al., 2009). Toxicity, rapid clearance from circulation and lack of tissue specificity are 
associated problems (Lasic, 1997; Li and Ma, 2001; Singh, 1998). Researchers are 
aiming to solve these problems. One solution for non-specific cellular uptake 
involves the attachment of a targeting moiety like transferrin, directed to a cognate 
site on a target cell. 
 
1.8 Targeted siRNA-Lipoplex Delivery  
 
Targeted gene delivery refers to the transport of nucleic acids to pre-defined cells 
and tissues for a specific therapeutic response (Burkhanov et al., 1988). Lack of cell 
or tissue specificity limits the in vivo application of liposomes and other non-viral 
vectors, as intravenous injection of siRNA delivery systems commonly results in 
accumulation or removal by the lung or liver, respectively (Hashida et al., 2000; Qi et 
al., 2005, Zhu et al., 1993). Targeting can be either ‘passive’ or ‘active’. Passive 
targeting refers to the natural localisation pattern of administered liposomes (Singh, 
1998). Active targeting involves either conjugation of a targeting moiety to the 
therapeutic molecule or encapsulation/binding by a ‘nanoparticle’ that contains a 
targeting component. It directs and enhances specific cellular uptake of siRNAs and 
other molecules (Seto et al., 2010; Singh, 1998). Targeted delivery generally utilizes 
specific and unique characteristics of particular cells to deliver therapeutic nucleic 
acids to the correct locale for effective genetic treatment (Singh, 1998). 
 
Examples of early gene targeting were accomplished by Wu and co-workers, an 
asialoglycoprotein coupled to poly-L-lysine for hepatocyte targeting (Wu and Wu, 
1988); and Wagner and colleagues, a polycationic-transferrin conjugate targeted to 
cancer cells (Wagner et al., 1990). Among the different methods of liposome 
targeting, attachment of a ligand to the vector surface is the most effective method 
of delivery to a selective site (Huang, 1999). Commonly utilized targeting ligands 




1997). When receptor ligands are incorporated into gene delivery systems, receptor 




1.8.1 Receptor Mediated Endocytosis for Targeted siRNA Delivery 
 
Receptor mediated endocytosis (RME) is a multi-step cellular mechanism for uptake 
of macromolecules, such as nutrients (LDL), growth factors (epidermal growth factor) 
and hormone (insulin), from the extracellular environment (Smythe and Warren, 
1991; Wolfe, 1995). It is an attractive mechanism for use in cell-specific gene delivery. 
The basic principle of receptor mediated gene delivery is to subvert RMEs efficient 
transport system so as to allow nucleic acids (siRNA/shRNA) complexed to ligands 
entrance into the target cell (Phillips, 1995). The actual RME mechanism (figure 1.13) 
involves binding of a ligand to specific membrane-spanning cognate receptors on the 
cell surface (Smythe and Warren, 1991). This leads to a conformational change in the 
receptor and results in clustering of receptor-ligand complexes within clathrin 
coated pits. Clathrin forms lattices on the plasma membrane, which undergo growth 
and rearrangement, resulting in invagination and scission of these pits to generate a 
coated endocytic vesicle. The vesicle is rapidly uncoated to form the early endosome 
(Phillips, 1995; Smythe and Warren, 1991; Wolfe, 1995). Within the endosome, 
ligands and receptors dissociate (acidic pH) and are sorted to their appropriate 
intracellular destinations (example: golgi apparatus or nucleus) (Smythe and Warren, 
1991; Templeton, 2008). Receptors may be degraded (lysosome) or recycled back to 
the cell surface for further rounds of uptake.  The late endosome fuses with 
lysosomes, leading to the degradation of ingested material, with, in some cases, 
release of the digested products into the extracellular fluid (Wolfe, 1995; Singh, 1998; 
Smythe and Warren, 1991).     
 
Incorporation of a targeting ligand into non-viral vector constructs such as liposomes 
has proven an effective method for gene delivery into target cells (Singh, 1998). An 




acids from the endosome prior to lysosome fusion, so as to avoid the degradation 
step (Rao, 2010).   
 
 
Figure 1.13: Mechanism of Receptor-Mediated Endocytosis (www.srs.dl.ac.uk)  
 
 
1.8.2 Hepatocyte-Targeted siRNA Delivery 
 
The liver is an attractive target tissue for an evolving technology such as RNAi 
therapeutics due to its large size, metabolic capacity, rich blood supply, active filter 
function and possession of large numbers of high affinity cell-surface receptors that 
can bind asialogylcoproteins (Kim et al., 2007; Nguyen et al., 2008). The 
asialogylcoprotein receptors on mammalian hepatocytes are known to be present at 
a density of 500 000 receptors per cell, exhibit high ligand affinity, rapid 
internalization rates, with retainment on several human hepatoma cell lines (Kim et 
al., 2007). Hepatocytes produce a large number of serum proteins and hold great 
appeal for siRNA therapy to correct defects, such as metastatic hepatocarcinomas, 




was shown in vitro and in vivo that hepatocytes, bearing on their surface 
asialoglycoprotein receptors, exhibited increased uptake of liposomes modified with 
ligands containing a terminal galactose residue (Hoekstra et al., 1978; Spanjer and 
Sherphof, 1983). 
 
1.9 Outline of Thesis 
 
siRNAs are emerging as new generation ‘bio-drugs’ due to their specific and potent 
RNAi triggering capabilities. However, siRNAs are anionic molecules that require 
transport across the cell membrane hence a major obstacle for their use in human 
therapeutics is efficient and specific cell delivery. Consequently carrier development 
is critical for its widespread clinical application (Oh et al., 2009; Singh et al., 2009). In 
this thesis we have investigated the in vitro delivery of hepatocyte-targeted cationic 
liposomes complexed to synthetic siRNA.  The liver is a particularly attractive target 
for RNAi therapeutics. Composed of one of the most physiologically active cells in 
the body (i.e. hepatocytes) and a site for synthesis of a wide range of serum proteins, 
the liver demonstrates a predisposition to a variety of genetic and metabolic 
diseases. Additionally, hepatocytes exclusively express large numbers of the high 
affinity asialoglycoprotein (ASGP) receptors that recognise and bind non-reducing 
termini of heteroglycans (Kawakami et al., 1998; Kim et al., 2007).  
 
Thus two previously synthesized cationic lipids, 3β [N-(N’,N’-
dimethylaminopropane)- carbamoyl] cholesterol (Chol-T) and 3β [N-(N’,N’,N’-
trimethylammonium propane iodide)- carbamoyl] cholesterol (Chol-Q), were 
incorporated into hepatocyte-targeted cationic liposomes for investigation of their in 
vitro siRNA delivery efficacy to the hepatocyte-derived human cell line, HepG2. 
Targeting was achieved by incorporation of the (β)-D-galactopyranoside ligand into 
the structure of the cationic liposomes. Untargeted cationic liposomes were also 
prepared for comparison. In chapter two the preparation of the liposomal 
components is described. In addition, the chapter also details the manufacture and 
characterization of the cationic liposomes. Characterization was achieved by cryo 




interaction by means of agarose gel electrophoretic retardation and the SYBR®green 
displacement assay. siRNA lipoplex characterization (via microscopy) and stability in 
10% foetal bovine serum (FBS) was also explored in this chapter. Chapter four 
focuses on the evaluation of siRNA lipoplex cytotoxicity and transfection efficiency as 
elucidated by delivery to transformed cells, ASGP-R+ HepG2 and ASGP-R- HEK293 , in 
culture.  
 
The main aim of this study was to design, synthesize and evaluate novel cationic 
liposomes as siRNA delivery vehicles targeted towards hepatoma cells in culture.  
The use of the (β)-D-galactopyranoside ligand was envisioned to provide specific 
uptake by hepatocytes, hence providing a more efficient siRNA delivery vehicle. This 





























Chapter Two : Liposome Preparation and Characterisation 
 
2.1 Introduction  
 
This chapter focuses on the preparation of four cationic liposomes, containing either 
the synthesized ternary cationic cholesterol derivative, Chol-T or the quaternary 
cationic cholesterol derivative, Chol-Q, with and without targeting elements. All 
liposomes were characterised by transmission electron microscopy.    
 
Liposomes are synthetic analogues of natural membranes and can be defined as 
spherical particles with one or more lipid membranes (Figure 2.1) enclosing part of 
the aqueous environment (Lasic and Papahadjopoulos, 1998). Liposome composition 
depends largely on the intended use, but generally consists of a phospholipid, a 
sterol and charged amphiphiles in varying ratios (Kinsky, 1974). Amphiphiles are 
molecules that contain a hydrophilic head group and a hydrophobic tail. Upon 
dispersion in an aqueous solution, these molecules self-assemble into ordered 
structures, such as lipid bilayers, which subsequently self-close to form liposomes, 
due to the unfavourable energy of the hydrophobic edges located adjacent to the 
water (Lasic, 1997; Singh, 1998). Phospholipids available for use in liposome 
synthesis are usually biodegradable and reusable. These include: phospholipids from 
natural sources, modified natural phospholipids, phospholipids with non-natural 
head groups, semi-synthetic and fully synthetic phospholipids (Chapman, 1983; 
Singh, 1998). 






Figure 2.1:  Schematic representation of a typical liposome lipid bilayer structure. 
 
Liposomes are characterised by their lipid composition, particle size distribution, 
number of lamellae and inner/outer aqueous phases (Lasic and Papahadjopoulos, 
1998). Liposomes, morphologically, range from small (S), large (L) and giant (G) 
unilamellar vesicles (UV) to multilamellar vesicles (MLV) (Lasic, 1997). Structurally, 
liposomes vary from long tubules to oval or spherical vesicles in shape (Singh, 1998). 
Liposome size and structure is dependent on the method of preparation employed. 
MLVs are the simplest liposomes to prepare. They are composed of multiple 
concentric lamellae separated by aqueous layers and range in diameter size from 
nanometers (nm) to micrometers (µm). Small unilamella vesicles (SUVs) are formed 
from sonication of MLVs and have a diameter range of 20-200 nm (Lasic, 1997; Lui et 
al., 2009). SUVs have previously displayed a propensity to aggregate and attach to 
larger structures due to their highly curved nature (Lui et al., 2009). Both MLVs and 
SUVs have low encapsulation efficiencies and are thus considered unsuitable for 
nucleic acid or drug delivery (Singh, 1998). LUVs range in size from 500 nm to several 
microns (Chapman, 1984; Lui et al., 2009). GUVs normally have diameters above 1 
µm (Lasic, 1997). Due to their large size, GUVs are sensitive to the slightest change in 
osmotic pressure, resulting in undulation or rupture of the vesicle (Lui et al., 2009).      
 
Most cationic liposomes consist of two lipid species, namely: a positively charged 
lipid and a neutral co-lipid (Lasic, 1997). Examples of commonly utilized cationic and 
neutral lipids can be seen in Figures 2.2 and 2.3, respectively.  The majority of 
positive charges of cationic lipids are based on (poly)amines and quaternary 
ammonium salts (Lasic, 1997). All cationic lipids have four functional domains, 
namely: one or more positively charged head groups, a spacer, a linker bond and a 
hydrophobic anchor. The role of the hydrophobic anchor is to ensure assembly into a 
lipid bilayer vesicle upon dispersion in an aqueous medium. The hydrophobic anchor 
is usually a cholesterol derivative or a double hydrocarbon chain (Lonez et al., 2008). 
The positively charged head group (s) is the nucleic acid binding moiety of the lipid 




between the cationic head group and the hydrophobic anchor; it determines lipid 
stability and biodegradability. Various chemical linkers have been utilized in lipid 
synthesis. These include: amide, amine, carbamate, ester, ether, urea and peptide 








Figure 2.2: Structures of four cationic lipids used in liposome formulations. DOSPA: 
1,3-dioleoyloxy-N-[2-(s-oxy[ethyl-2-heptadecenyl-3 hydroxyethyl] imidazolinium 
chloride; DOSPER: 1,3-dioleoyloxy-2-(6-carboxyspermyl)-propylamide; DOTAP: 1,2-
dioleoyl-3-dimethylammoniumpropane; DOGS: dioctadecylamidoglycylspermine 

















Figure 2.3:  Examples of neutral lipids used in cationic liposome formulations. DOPE: 
dioleoylphosphatidylethanolamine; (Lasic, 1997; Mēvel et al., 2010). 
An important parameter in liposome formation is the rigidity of the bilayer. Hydrated 
single component phospholipid bilayers are characteristically in a liquid crystalline 
(fluid) or gel state. Phospholipids are characterised by their phase transition 
temperature (Tc), which allows transition of membranes from a fluid to a gel state. 
Bilayer Tc depends on the acyl chain length, polar head group and degree of 
saturation. Increased acyl chain lengths and saturation result in an increased Tc value 
(Lasic, 1997; Crommelin and Schreier, 1999 ; Singh, 1998).  
 
Liposomes can be synthesized through a variety of methods (Table 2.1.). These 
preparation techniques are broadly classified into several categories according to the 
basic mode of dispersion, example: mechanical dispersion, solvent dispersion and 
detergent solubilization (Gregoriadis, 2007).  The simplest method for liposome 
formation is the shaking or film method. This is a mechanical method, originally used 
by Bangham et al, that produces liposomes by shaking hydrated thin-lipid films 
above the Tc, yielding MLVs of a heterogenous population size (Bangham et al., 
1965). Another mechanical method employs sonication of aqueous phospholipid 
dispersions, yielding SUVs. It can be performed via two different approaches. The 
first employs a sonication probe placed directly into the liposome suspension, while 
the second utilizes a sonication bath. Although the latter is a slower method, it 
decreases contamination of the liposomes (Crommelin and Schreier, 1999; Maguire 
et al., 2003).  
 
During the reverse-phase evaporation method, formation of a reverse-phase 
emulsion (water-in-oil dispersion) is followed by evaporation of the organic phase. 
This results in a gel consistency of aqueous vesicles bounded by a phospholipid 
monolayer. Mechanical agitation ruptures some vesicles, with the released 
phospholipid acting as the outer monolayer, converting other vesicles into LUVs (Kim 
et al., 1993; Philippot, 1995). Homogeneous populations and high encapsulation 







Table 2.1: Various techniques for Liposome synthesis  
 
 
 METHOD SIZE REFERENCE 
1. Hand-shaken preparation MLV Bangham et al., 1965 
2. Sonication SUVs Johnson et al., 1971 
3. Extrusion by Filters SUVs/LUVs Lasic, 1997 
4. Homogenisation SUVs/MLVS Lasic, 1997 
5. Ether Injection LUVs Deamer and Bangham, 1976 
6. Ethanol Injection SUVs Batzi and Korn, 1973; 
Campbell, 1995 
7. Detergent Depletion SUVs Torchilin, 2003 
8. Reverse-Phase Evaporation LUVs Szoka and Papahadjopoulos, 
1978 
9. Thin lipid Film Hydration  SUVs/LUVs Gao and Huang, 1991 
10. Calcium-induced Fusion  
 




MLVs/LUVs Mayhew et al., 1984 
 
The extrusion technique employs filters of various pore sizes (0.2 – 500 nm) through 
which lipid dispersions are passed. It yields the best vesicles with respect to 
homogenously sized populations (Lasic, 1997). It can be employed in combination 
with other techniques. A variation of this technique is freeze-thaw extrusion, where 
liposomes formed by the film method are vortexed with the solute to be entrapped 
until the entire film is suspended. The resulting vesicles are frozen in a dry ice/ 




multiple times (Chapman et al., 1991).  The choice of liposome preparation 
technique depends on the purpose, availability of equipment and liposome size 
required. It is important to note that some of the above mentioned techniques 
cannot be employed for cationic liposome synthesis. These include: detergent 
depletion, ether and ethanol injection (Lasic, 1997).       
 
The aim of this chapter was to present the preparation of targeted (Figure 2.4) and 
untargeted cationic liposomes comprised of: 3β [N-(N’,N’-dimethylaminopropane)-
carbamoyl] cholesterol (Chol-T) or 3β [N-(N’, N’, N’-trimethylammoniumpropyl)-
carbamoyl] cholesterol  iodide (Chol-Q) and DOPE, with and without cholesteryl β-D-
galactopyranoside ligands. The liposomes, once synthesized, were subjected to 
























Dioleoylphosphatidylethanolamine (DOPE) was purchased from the Sigma Chemical 
Company, St Louis, USA. Cholesteryl chloroformate, 2-[4-(2-hedoxyethyl)-1-
piperazinyl] ethanesulphonic acid (HEPES), 3-dimethylaminopropylamine, silica gel 
beads (60 µm) and silica gel F254 chromatography plates were  purchased from Merck, 




2.3.1 Preparation of Cationic Cholesterol Derivatives 
 
The cholesterol derivatives (Chol-T and Chol-Q) were previously synthesized in our 
laboratory as follows: 
 
2.3.1.1 Chol-T Synthesis  
 
3-dimethylaminopropylamine (62.8 µl, 0.11 µmoles) was added to a solution of 
cholesteryl chloroformate (90 mg, 0.2 µmoles) in 1 ml dichloromethane. The 
synthesis reaction (Figure 2.5 a) was allowed to proceed at room temperature for 
one hour and was monitored by thin layer chromatography (TLC) in a chloroform : 
methanol (95 : 5 v/v) solvent system (A) (result not shown). The solvent 
(dichloromethane and excess 3-dimethylaminopropylamine) was subsequently 
removed by rotary evaporation in a Büchi Rotavapor-R. The resulting residue was 
dissolved in absolute ethanol and allowed to crystallise overnight at 4°C. The product 
was subsequently recrystallised, filtered under a stream of dry nitrogen gas and 
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Figure 2.5: Synthesis scheme for the cholesterol derivatives, Chol-T and Chol-Q, 
where C= cholesteryl chloroformate, T= Chol-T, 3β [N-(N’,N’-
dimethylaminopropane)-carbamoyl] cholesterol, and Q= Chol-Q, 3β [N-(N’,N’, N’-
trimethylammonium propane iodide)-carbamoyl] cholesterol iodide. 
 
 
2.3.1.2 Chol-Q Synthesis  
 
Methyl iodide (1.5 molar excess) was added to an ether solution of Chol-T (Figure 2.5 
b). The reaction was then centrifuged at 3000rpm for 5 minutes in an MSE bench top 
centrifuge.  The resulting pellet was suspended in dry ether (10 ml) and re-
centrifuged as before. The pellet was then dried under vacuum at room temperature, 
prior to re-crystallization from hot ethanol, yielding a crystalline product. The 
reaction was also monitored by TLC in solvent system A (result not shown). Both 
Chol-T and Chol-Q were subjected to melting point determination and to 250 MHz 
proton spectrometry (Figure 1 and 2, Appendix A).  
  
2.3.2 Isolation and De-acetylation of Per-acetylated Cholesteryl-β-D-  
          Galactopyranoside 
 
The isolation and de-acetylation of per-acetylated cholesteryl β-galactose was 
previously performed in our laboratory as follows: 
 
The reaction mixture from Koenigs Knorr synthesis of per-acetylated cholesteryl-β-D-
galactopyranoside was purified via column chromatography, yielding per-acetylated 
cholesteryl-β-D-galactopyranoside. The column (257 mm x 26 mm) was packed with 
a slurry of silica gel beads (60 nm) in a hexane : ethyl acetate (8 : 3 v/v), solvent 
system (B). The reaction mixture was added to the column and collected upon 
elution in fractions over a period of approximately 3 hours. Fraction samples were 
monitored by TLC in solvent system B (result not shown). Fractions containing the 
per-acetylated cholesteryl-β-D-galactopyranoside were pooled, prior to evaporation 





The per-acetylated cholesteryl-β-D-galactopyranoside (75.8 mg, 0.105 µmoles) was 
then dissolved in anhydrous chloroform (7.58 ml), followed by the addition of 
sodium ethoxide (1.05 µmoles). The de-acetylation reaction was allowed to proceed 
for 24 hours at room temperature and was monitored by TLC in a formic acid : ethyl 
acetate : chloroform (1 : 5 : 4 v/v/v), solvent system (C) (result not shown). The 
product yield was quantitative.   
 
2.3.3 Preparation of Cationic Liposomes 
 
The cationic liposomes were prepared by a method modified from that employed by 
Goa and Huang (1991). The relative quantities of the components of the cationic 
liposomes were as set out in Table 2.2.  
 
Table 2.2: Lipid composition of cationic liposomes, where β-GAL1 represents 




Briefly, the components of each cationic liposome preparation were deposited as a 





























2 - 2 - 1.029 - 1.488 - 
SD-CholT Targeted 
(SD-CholTT) 
2 - 2 0.5 1.029 - 1.488 0.280 
SD-CholQ Control 
(SD-CholQC) 
- 2 2 - - 1.310 1.488 - 
SD-CholQ Targeted 
(SD-CholQT) 




then dried for 1 hour in a drying pistol, prior to rehydration overnight in 1 ml of 
sterile HEPES buffered saline (20 mM HEPES and 150 mM NaCl, pH 7.5). The mixtures 
were vortexed, sonicated for 1 minute and left for 24 hours at 4°C. The mixtures 
were subsequently sonicated for a further 5 minutes to produce unilamellar 
liposomes. Each liposome preparation contained a total of 4 µmoles of lipid. 
Liposomes were stored at 4°C and sonicated prior to use.     
 
2.3.4 Characterization of Liposomes by Transmission Electron Microscopy (TEM) 
 
Liposomes were diluted (1:5) with HEPES buffered saline. Thereafter, 1 μl of 
liposome solution was added to formvar (polyvinyl formal)-coated grids, followed by 
addition of 1 μl of 1% uranyl acetate. The grids were immediately blotted with filter 
paper to remove excess moisture and subsequently vitrified by plunging into liquid 
ethane using a Leica CPC system. Grids were then transferred to a Gatan 
cryotransfer system and viewed using a JEOL-1010 transmission electron microscope, 
























2.4 Results and Discussion 
 
2.4.1 Preparation of Cationic Cholesterol Derivatives 
 
Both cationic cholesterol derivatives, Chol-T and Chol-Q, were previously successfully 
synthesized by Singh (1998). Chol-T had a melting range of 103-105°C, and Chol-Q 
had a melting range of 168-170°C when subjected to melting point determination. 
1H-NMR spectroscopy of the derivatives (Figure 1 and 2, Appendix A) showed 
singlets at δ 2.19 and δ 3.4 which were characteristic of tertiary methyl amino and 
quaternary methylammonium headgroups respectively (Singh, 1998).   
 
  
Chol-T:  δ 2.19 (singlet, 6H, (CH3)2NCH2CH2); 
  δ 2.30 (triplet, 2H, (CH3)2NCH2CH2CH2NH); 
  δ 3.21 (quartet, 2H, (CH3)2NCH2CH2CH2NH); 
  δ 5.35 (doublet, 1H, (CH3)2NCH2CH2CH2NH) 
 
Chol-Q: δ3.30 (quartet, 2H, (CH3)2NCH2CH2CH2NH); 
  δ 3.40 (singlet, 9H, (CH3)3NCH2CH2); 
  δ 3.75 (triplet, 2H, (CH3)2NCH2CH2CH2NH); 
  δ 5.34 (doublet, 1H, (CH3)2NCH2CH2CH2NH)  
 
 




Chol-T (Figure 2.6 a) and Chol-Q (Figure 2.6 b) both have a cholesterol ring structure, 
a carbamoyl linker bond and a spacer arm. They differ in the head group, with Chol-T 




trimethylammonium head group. Cationic lipids can broadly be divided into two 
classes, namely:  (i) those that have cholesterol as their lipid anchor and (ii) those 
that utilize diacyl chains (Huang, 1999). Cholesterol anchors generally lead to more 
active cytofectins than their diacyl counterparts (Lee et al., 1996). The cholesterol 
anchor provides rigidity to the liposome structure, as well as influencing membrane 
fluidity.  
 
 It has been reported that when a carbamoyl unit is employed as the linker bond, the 
lipid has increased degradability and therefore is potentially less toxic to the target 
cells both in vitro and in vivo (Goa and Hui, 2001). The relatively labile carbamoyl 
bond is more stable and not as easily hydrolysed as ester bonds, but once inside the 
cell it is quite easily degraded by cellular esterases (Lasic and Papahadjopoulos, 1998; 
Lee et al., 2005). The length of the spacer arm is purported to play a role in the 
interaction between the charged head groups and the nucleic acid. A longer spacer 
arm is said to result in decreased steric hindrance between the polar head group and 
the hydrophobic anchor (Singh, 1998).  A spacer arm consisting of between three 
and six carbon atoms between the amino group and the linker bond was also 
reported to provide the optimal distance for efficient gene delivery activity (Goa and 
Hui, 2001).  
 
The positively charged head group of a cationic lipid is the most important domain in 
determining the overall efficiency of gene delivery characteristics for the particular 
cationic lipid (Goa and Hui, 2001). It also plays an important role in determining 
cytotoxicity of the liposome (Huang et al., 1999). Multivalent head groups, although 
more active than their monovalent counterparts  such as Chol-T and Chol-Q, can 
render the cationic liposome more water-soluble, leading to a greater propensity to 
form micelles, which in turn may lead to less stable, more toxic liposomes (Huang et 
al., 1999). Lipids bearing linear amines or polyamines as the positively charged head-
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Figure 2.7: Structures of (a) Chol-T and (b) Chol-Q showing the four basic domains 






2.4.2 Isolation and De-acetylation of Per-acetylated Cholesteryl-β-D- 
         Galactopyranoside 
 
The isolation and de-acetylation of per-acetylated cholesteryl-β-D-galactopyranoside 
was previously successfully performed in our laboratory. Fractions collected from 
column chromatography on silica gel 60 were subjected to TLC, prior to pooling of all 
per-acetylated cholesteryl-β-D-galactopyranoside containing fractions. A 
confirmation test was then performed, where the per-acetylated cholesteryl (β)-D-
galactopyranoside was run on a TLC plate against a standard, as well as the starting 
reaction mixture. All TLC plates were sprayed with 10% sulphuric acid to aid in 
visualization via colour development. Acid causes dehydration of sterols and free 
sugar resulting in a pink/purple and brown/black colour, respectively.  The acetate 
protecting groups were then removed by treatment with an excess of sodium 
ethoxide, an alkoxide salt (Figure 2.8). Successful de-acetylation was demonstrated 
by running the reaction product against acetylated and non-acetylated standards on 






















Figure 2.8: Reaction scheme showing the de-acetylation of per-acetylated 
cholesteryl-β-D-galactopyranoside, where (a) represents the per-acetylated 
cholesteryl-β-D-galactopyranoside and (b) cholesteryl-β-D-galactopyranoside.  
Different methods exist for attachment of ligands to liposomes i.e. covalent, non-
covalent or incorporation via a hydrophobic anchor (Philippot, 1995). The latter 
method was used in this investigation. The asialoglycoprotein receptor on 
mammalian hepatocytes specifically recognises ligands with terminal glucose, 
galactose or N-acetylgalactosamine residues (Wu et al., 2002). Research previously 
performed in our laboratory by Singh et al. (2007), determined that the β-anomer of 
galactose (Figure 2.8) demonstrates superior transfection ability as compared with 
the α-anomer, as well as α-and β-glucose residues. Thus it was chosen as the 
targeting element in our liposome formulations. 
 
2.4.3 Preparation of Cationic Liposomes 
 
Cationic liposomes were successfully prepared using the method described. This was 
demonstrated by transmission electron microscopy (2.3.4) and positive electrostatic 
interaction with siRNA (chapter three). The control cationic liposomes were 
prepared using an equimolar amount of either Chol-T or Chol-Q and DOPE. Their 
targeted counterparts contained an additional 11 mole % cholesteryl-β-D-
galactopyranoside. The synthesis method (lipid film hydration/sonication) used, 
proved simple and efficient. 
 
The 1 : 1 molar ratio of cytofectin to co-lipid was chosen because it was previously 
employed with great success in our laboratory (Singh, 1998). Research done by 
Farhood et al. (1995) and Maitani et al. (2007) also suggested that either a 3 : 2 or  




1 : 1 ratio of a similar cytofectin (DC-chol) with DOPE demonstrated high transfection 
activity; while Zhang et al. (2010) demonstrated that a DC-chol/DOPE molar ratio of 
1 : 1 showed the highest transfection efficiency with regard to siRNA delivery. The 
control liposomes were synthesized to demonstrate that increased transfection 
efficiency of HepG2 cells (target cell line) occurred through receptor mediated 
endocytosis via the asialoorsomucoid receptor.  
 
DOPE, a neutral zwitterionic phospholipid, is the most prevalent co-lipid used in 
liposome formulations due to its ability to increase transfection efficiency and 
reduced cytotoxicity of the cationic surfactant (Hoekstra et al., 2007; Sternberg et al., 
1994). DOPE has an inverse-conical molecular shape that is wide at the termini of the 
dioleoyl fatty acid side chains and narrow at the polar head group (Mēvel et al., 2010) 
(Figure 2.3). It is this molecular shape that facilitates liposomal cellular interaction 
and endosomal escape. This fusogenic lipid has a tendency to form a hexagonal Hll 
phase, thus moving the liposomal membrane away from lamellar order and 
destabilising it, which is critical for fusion of the liposomal and endosomal 
membranes (Hoekstra et al., 2007; Lasic, 1997; Mēvel et al., 2010; Singh, 1998; 
Zuhorn et al., 2005).  
    
2.4.4 Characterization of Liposomes by Transmission Electron Microscopy (TEM) 
 
Transmission electron microscopy revealed the unilamellar nature and sizes of the 
different cationic liposomes (Figure 2.9). A heterogeneous population size was 
obtained for all liposome preparations. The majority of liposomes ranged from 80 
nm to 200 nm in size, although liposomes up to ±400 nm were also observed. The 
untargeted liposomes containing Chol-T were, on average, slightly smaller (± 30 - 50 
nm) than those containing the Chol-Q derivative. This is in accordance with results 
obtained by Singh et al. (1998) during microscopy studies of liposomes with the 
same molar ratios and lipid composition. No significant size difference was observed 
for the targeted and untargeted liposomes. All liposome preparations were generally 




Note that any artefacts seen in the TEM micrographs can be attributed to the 
cryoTEM process.       
 
Size is an important factor for liposome circulation time and internal accumulation 
(Düzgünes, 2004; Lee et al., 2005). Generally, smaller liposomes (<100 nm) are 
slowly eliminated from the blood as compared with larger liposomes, which are 
rapidly taken up by Kupffer cells (Düzgünes, 2004). Studies performed by Lui et al. 
(2003) showed that liposomes less than 70 nm in diameter were predominantly 
taken up by the liver (parenchymal cells), while those that were greater then 200 nm 
were preferentially taken up by the spleen. Vesicle size characterization can be 
performed using a variety of techniques, including: dynamic light scattering (DLS), gel 
exclusion chromatography, specific turbidity, sedimentation field-flow fractionation, 
coulter counter, light diffraction and electron microscopy (EM) (Korgel et al., 1998; 
Lasic, 1997). DLS and EM are the most widely employed of the above techniques. 
While EM generally provides an evaluation of liposome lamellarity and size, DLS 











           
 
 
Figure 2.9: Transmission electron microscopy with negative staining, of the four 
liposome preparations. Bar = 100 nm; (a) SD-CholTC, (b) SD-CholTT, (c) SD-CholQC 
and (d) SD-CholQT. 
 
 
Negative staining, freeze-fracture and cryoelectron microscopy are among the most 
widely employed EM techniques (Lasic, 1997). Negative staining is prone to artefacts 
as a result of vesicle dehydration, while the unknown plane during freeze-fracture is 
a hindrance. Cryoelectron microscopy, although more reliable, suffers from poor 
visualization due to a lack of contrast between the liposome and the background. 
Hence, during this investigation negative staining in combination with cyroTEM was 
employed. The problem of vesicle dehydration was eliminated by testing a range of 
negative stains at various incubation periods. Results obtained indicated that 1% 
uranyl acetate, with immediate blotting, demonstrated little or no dehydration of 
liposomal vesicles.            
 
In this chapter, cationic lipids were successfully synthesized and formulated into 
liposomes containing the Cholesteryl-β-D-galactopyranoside targeting ligand. 
Cationic liposome characterisation by cryoTEM revealed a generally homogeneous 























Chapter Three: siRNA-Cationic Liposome Interaction and 
Characterisation 
 
3.1 Introduction  
  
The understanding of siRNA-cationic liposome interaction is vital for the optimisation 
of transfection efficiency with the overall aim of achieving clinical application as a 
genetic therapy. This chapter focuses on the interaction between the cationic 
liposomes synthesized as described in chapter two and siRNA. It evaluates and 
details the characterisation, binding and protection efficiency of the resultant siRNA 
lipoplexes.       
 
The term lipoplex, first coined by Felgner et al. (1987) was initially, exclusively used 
to describe the complexes formed between cationic liposomes and DNA.  With the 
growth of gene therapy and the advent of RNAi, this concept was expanded to 
include Oligodeoxynucleotides (ODNs), miRNAs and siRNAs. Hence, a more concise 




and nucleic acids (Guo et al., 2010). Lipoplex formation is generally achieved by 
incubating the nucleic acid with the cationic liposome solution under well defined 
conditions of pH and salt strength (Felgner et al., 1987). The formation of nucleic 
acid–cationic liposome complexes is a highly co-operative process involving 
spontaneous ionic interaction between the positively charged head groups of the 
cationic lipid and the negatively charged phosphate backbone of the nucleic acid (De 
Paula et al., 2007; De Rosa et al., 2009; Huang et al., 1999; Ma et al., 2007). The 
physiochemical properties of the resultant complexes are dependent on: (i) the type 
and relative proportions of nucleic acid and cationic lipid, (ii) liposome size, (iii) 
presence of neutral lipids, (iv) nature of head group of the cationic lipid, (v) the 
charge ratio and (vi) temperature, amongst other factors (De Paula et al., 2007; De 




                        
 
Figure 3.1: Illustrations of the (a) electrostatic model of DNA lipoplexes and (b) the 
coated electrostatic model resembling ‘spaghetti and meatball-like ‘DNA-liposome 
complexes (Singh, 1998; Sternberg et al., 1994). 
 
Conventional DNA-cationic liposome complexes have been extensively characterized, 
with several models being proposed describing the nature of complexation, including 
the electrostatic and coated electrostatic models (Figure 3.1) (Lasic, 1997; Marty et 
al., 2009). However, despite considerable knowledge and investigations into DNA- 







cationic liposome complexes, little is known about siRNA/RNA-cationic liposome 
interactions (Marty et al., 2009). Of critical importance is the fact that DNA and 
siRNA are completely different types of nucleic acids (De Paula et al., 2007; Lu et al., 
2009).  Although both are double-stranded with anionic phosphodiester backbones 
composed of the same nucleotide to negative charge ratio and they can each 
interact electrostatically with cationic liposomes, the size and ionic charge of siRNAs 
are much smaller than those of DNA. siRNAs have a molecular weight of ± 15 kDa, 
compared to the ± 10 000 kDa of plasmid DNA (Lasic, 1997; Schiffelers et al., 2005). 
These differences in molecular weight and topography mean that theoretically, 
siRNA cannot condense into particles of nanometric dimensions due to their already 
compact size and rigidity (De Paula et al., 2007; Lu et al., 2009; Rhinn et al., 2009). A 
recent study by Marty et al. (2009) demonstrated that smaller RNA molecules, in this 
case tRNA, preserved its folded state when complexed to cationic lipids, whereas 
DNA-lipid complexes induced partial B to A and B to C conformational changes 
within the DNA. Although tRNAs are on average four times large than siRNAs, they 
are still considerable smaller than DNA, providing some sort of tangible evidence 
that supports the theory that siRNA behaves differently when complexed to cationic 
liposomes compared with DNA.  Bouxsien et al. (2009) revealed the isotropic 
ordering of siRNA in siRNA-cationic liposome complexes compared with the smectic 
ordering of DNA observed in DNA-cationic liposome complexes. They hypothesized 
that this difference in spatial ordering may prevent optimal siRNA packaging, 
resulting in decreased efficiencies as compared with DNA lipoplexes (Bouxsein et al., 
2009). Much ambiguity still surrounds the field of siRNA delivery, however various 
studies have provided preliminary insight into the nature of siRNA : cationic 
liposome interaction.            
 
In this investigation we utilized the gel retardation and dye displacement assays to 
assess siRNA lipoplex formation and elucidate binding/condensation abilities for all 
cationic liposome preparations. The gel retardation or band shift assay was adapted 
for use with cationic liposomes from the method originally employed by Fried and 
Crothers (1981) for studying DNA-protein interactions. It exploits the charge 




(Huang et al., 1999). The dye displacement assay exploits the fluorescence-
quenching that siRNA bound to an intercalating dye exhibits in the presence of 
cationic liposomes (Dorasamy et al., 2009). The ability of cationic liposomes to 
protect its cargo (i.e. siRNA) from nuclease degradation was ascertained through the 
nuclease protection assay. Finally, microscopy was also employed to provide visual 












siGenome non-targeting siRNA (control siRNA) and siCONTROL TOX siRNA (siTOX) 
were purchased from Thermo Sciencific Dharmacon, Lafayette, CO. SYBR®green ll 
nucleic acid gel stain (10 000x concentrate in DMSO) was obtained from Cambrex Bio 
Science Rockland Inc, Rockland, USA. Molecular biology grade agarose was 
purchased from Bio-Rad Laboratories, California, USA. Foetal bovine serum (FBS) was 
obtained from Highveld Biological (PTY) Ltd., Lyndhurst, South Africa. All other 




3.3.1 Reconstitution of siRNA and Preparation of siRNA-Cationic Liposome 
Complexes (siRNA Lipoplexes) 
 
siRNA was reconstituted as per the manufacture’s recommendation.  1 ml of 18 ohm 




nucleic acid solutions were subsequently aliquoted into micro-eppendorf tubes and 
stored at -20°C.  
 
To a constant amount of either control siRNA or siTOX (0.5 µg), varying amounts of 
cationic liposome (0 to 16 µg) was added. Lipoplex samples were then made up to a 
final volume of 10 µl or 13 µl (nuclease assay only) with HEPES buffered saline (HBS) 
(20 mM HEPES, 150 mM NaCl, pH 7.5). Complexes were allowed to incubate at room 
temperature (25⁰C) for a minimum of 30 minutes prior to use.     
 
3.3.2 Gel Retardation Assay 
 
siRNA lipoplexes were prepared as described in 3.3.1., with control siRNA. 2 µl of gel 
loading buffer (50% glycerol, 0.05% bromophenol blue, 0.05% xylene cyanol) was 
added to all lipoplex samples.  The samples were then subjected to electrophoresis 
on a 2% agarose gel in a Bio-Rad  mini-sub cell electrophoresis apparatus containing 
1x electrophoresis buffer (36 mM Tris-HCL, 30 mM sodium phosphate, 10 mM EDTA, 
pH 7.5), for 40 minutes at 50 volts. The gel was subsequently stained in a 
SYBR®green  solution (1:10 000 dilution) in TBE buffer (89 mM Tris base, 89 mM 
boric acid, 1 mM EDTA, pH 8) for 20 minutes with constant shaking on a Stuart 
scientific shaker . The gel was then viewed under UV transillumination using the 
Vacutec Syngene G:Box gel documentation system with short pass filter.  
 
3.3.3 SYBR®Green Displacement Assay 
 
Fluorescence measurements were conducted on a Shimadzu RF-551 
spectrofluorometric detector set at an emission wavelength of 520 nm and an 
excitation wavelength of 497 nm. 50 µl of a 1000x dilution of SYBR®green (10 000x 
concentrate) was made up to 500 µl with HBS (20 mM HEPES, 150 mM NaCl, pH 7.5). 
The fluorescence was measured to obtain a baseline relative fluorescence of 0. 
Thereafter, 5 µl (1.3 µg) of control siRNA was added to the baseline solution and the 
reading taken was assumed to represent 100% relative fluorescence. Subsequently, 




stepwise to the solution until a plateau and/ or approximately 40 µg of liposome was 
added. The solution was thoroughly mixed after each addition to promote even 
distribution prior to measurement of fluorescence. The results were plotted relative 
to the 100% fluorescence value. This procedure was conducted for all liposome 
preparations.     
 
3.3.4 Nuclease Protection Assay 
 
SiTOX at three concentrations: 25 nM, 50 nM and 100 nM, were complexed to 
varying amounts of cationic liposome (Table 3.1.) as described in 3.3.1. Thereafter, 
FBS was added to the complexes to a final serum concentration of 10% (v/v). 
Negative and positive controls were also setup (at the various siTOX concentrations) 
containing siTOX alone and siTOX with FBS, respectively. All reaction mixtures were 
then incubated at 37°C for 4 hours. Thereafter, ethylenediaminetetraacetic acid 
(EDTA) was added to the reaction mixtures to a final concentration of 10 mM and 
sodium dodecyl sulphate (SDS) to a final concentration of 0.5% (w/v). Reaction 
mixtures were incubated for a further 20 minutes at 55°C. The samples were then 
subjected to electrophoresis on a 2% agarose gel (as per 3.3.2) for 60 minutes at 50 
volts. The gel was subsequently stained in a SYBR®green solution (as per 3.3.2) for 20 
minutes with constant shaking on a Stuart scientific shaker and viewed under UV 
transillumination using the Vacutec Syngene G:Box gel documentation system with 
short pass filter.       
 
 
Table 3.1: The amount of liposome in lipoplex preparations used in the nuclease 
protection assay. Reaction mixtures contained 0.5 µg control siRNA. 
 
 
Liposome Preparation Liposome Amount 
 (µg) 




2. SD-CholTT 11 12 13 
3. SD-CholQC 10 11 12 
4. SD-CholQT 13 14 15 
 
 
3.3.5 TEM of siRNA Lipoplexes 
 
 SiRNA lipoplexes were prepared as described in 3.3.1, with control siRNA. The 
lipoplexes were then diluted (1:5) with HBS. Thereafter, 1 μl of liposome solution 
was placed on formvar-coated grids, followed by the addition of 1 μl of 1% uranyl 
acetate. The grids were blotted after 3 minutes with filter paper to remove excess 
moisture and immediately vitrified by plunging into liquid ethane using a Leica CPC 
system. Grids were then transferred to a Gatan cryotransfer system and viewed 
using a JEOL-1010 transmission electron microscope, without warming above -150°C. 
 
3.4 Results and Discussion 
 
3.4.1 Preparation of siRNA Lipoplexes 
 
siRNA lipoplexes were successfully prepared as demonstrated by gel retardation 
assays (3.4.2), dye displacement studies (3.4.3) and transmission electron 
microscopy (3.4.5). The method employed for lipoplex formation proved to be both 
simple and efficient. For our investigation, two different types of siRNA were utilized. 
The siGENOME non-targeting siRNA (control siRNA) and siCONTROL TOX siRNA 
(siTOX) molecules were reconstituted as per the manufacturer’s recommendation.  
 
The control siRNA was employed for the majority of characterization studies with the 
cationic liposomes; as well as growth inhibition studies (chapter four). It has a 
comparable GC content to that of functional siRNA, but lacks homology with known 
target genes in that it has four mismatches with all identified human, rat and mouse 




use of siTOX. It has a comparable molecular weight to that of the control siRNA, 
however it is a functional siRNA molecule that upon entering the cell induces 
programmed cell death (www.dharmacon.com). Hence it has been extensively 
utilized for analysis of transfection efficiency, especially as an initial indicator of 
vector or delivery efficacy in siRNA knock-down/out investigations (Yadava, 2007; 
www.dharmacon.com). Once generated, the siRNA lipoplexes were subjected to 




3.4.2 Gel Retardation Assay 
 
The results of the agarose gel electrophoresis of the siRNA-CholT and siRNA-CholQ 
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Figure 3.2: Gel retardation study of the binding interaction between control siRNA 
(0.5 µg) and increasing amounts of cationic liposomes containing Chol-T (a) SD-
CholTC  and (b) SD-CholTT , where: Lane 1: control siRNA alone (0.5 µg) and Lane 2 – 
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Figure 3.3: Gel retardation study of the binding interaction between control siRNA 
(0.5 µg) and increasing amounts of cationic liposomes containing Chol-Q. (a) SD-
CholQC  and (b) SD-CholQT , where: Lane 1: control siRNA alone (0.5 µg); (a) Lanes 2 
– 8: siRNA (0.5 µg) with varying amounts of cationic liposome (6, 7, 8, 9, 10, 11, 12 
µg); (b) Lanes 2 – 10: siRNA (0.5 µg) with varying amounts of cationic liposome (8, 9, 
10, 11, 12, 13, 14, 15, 16 µg). 
 
The results demonstrate that the cationic liposomes are able to bind siRNA for all 
liposome preparations tested. Lane 1 of each gel contained 0.5 µg control siRNA, 
which was shown to produce a single band within the agarose gel upon 
electrophoresis. As the liposome concentration of each preparation increased, more 
siRNA was bound to the liposomes and hence less siRNA was free to enter the gel. 
This is demonstrated by the gradual decrease in fluorescence of the bands within the 
gels. Complete retardation of the siRNA occurred at various siRNA : liposome ratios 
for the different liposome preparations  as set out in Table 3.2. Complete retardation 
is seen by the lack of a band within the gel. Agarose gel electrophoresis is used to 
demonstrate complex formation between the negatively charged siRNA and the 
positively charged liposomes. Gel electrophoresis is a standard method used to 
separate, identify and purify charged molecules, such as nucleic acids, through 
application of an electric field (Guilliatt, 2002). Naked siRNA subjected to 
electrophoresis migrates through the gel matrix. However, upon binding to the 
cationic liposomes, the negative charges of the siRNA are neutralised or titrated by 





two. Therefore, the neutral or slightly positively charged lipoplexes are ‘retarded’ 
and remain within the wells of the gel. Complete retardation suggests that all the 
negative charges of the siRNA are completely titrated by the positive charges of the 
cationic liposomes. 
 
Although small molecules (eg. RNA) are generally subjected to polyacrylamide gel 
electrophoresis, while larger molecules (eg. plasmid DNA) are analysed on agarose 
gels (Guilliatt, 2002), studies performed by Read et al. (2005) and Han et al. (2008) 
demonstrated successful use of agarose gels for siRNA retardation experiments. The 
above, combined with its availability and ease of preparation and use meant that 
agarose gels were used in this investigation. Various w/v percentages of agarose (i.e. 
1%, 2% and 3%) were tested to determine the best concentration for our purposes. 
The 2% agarose gel demonstrated adequate resolution and slower siRNA gel 
migration rates and was consequently selected for use.  As shown by the results 
(Figures 3.2 and 3.3) all cationic liposome preparations successfully bound the siRNA 
at varying ratios.      
















It is interesting to note that the overall results of the binding assay demonstrate that 







siRNA : Liposome 
Ratio (w/w) 
1. SD-CholTC 9 1 : 18 
2. SD-CholTT 12 1 : 24 
3. SD-CholQC 11 1 : 22 




with conventional DNA-liposome binding interaction. This result is in accordance 
with studies performed by Bouxsein et al. (2007), Watanabe et al. (2007) and Rhinn 
et al. (2009), all of whom demonstrated the need for a substantial increase in 
cationic liposome mass to form complexes with siRNA. These results seem to 
support the theory that siRNA are unable to condense into smaller structures during 
complex formation with cationic liposomes due to their already small size.   
 
From the results obtained it can be seen that more of the SD-CholQ liposomes were 
required to bind the same amount of siRNA as compared with the SD-CholT 
liposomes. This maybe attributed to the large molecular weight difference between 
Chol-T and Chol-Q iodide, which affects formulation. However when considering the 
positive (+)/negative (-) charge ratios of lipoplexes, differences between the two 
liposome species are small (Table 3.3). It must be remembered however that the 
monocationic head groups differ in methyl group substitution and the resultant 
difference in spatial structure may contribute to observe differences in optimum 
binding ratio. A similar result was observed by Kawakami et al. (2000b) who showed 
that a greater amount of liposome composed of the quaternary cationic lipid, 
DOTMA was required to bind a given amount of nucleic acid (DNA) compared with 
liposome containing the ternary cationic lipid, DC-Chol.  
 
The gel retardation results also show that cationic liposomes containing the 
galactose targeting ligand (SD-CholTT and SD-CholQT) seem to be less positively 
charged than cationic liposome preparations lacking this targeting ligand (SD-CholTC 
and SD-CholQC). A plausible reason for this observed trend could be due to the steric 
shielding effect of the targeting ligand. The β-galactose pyranoside ligand contains a 
lipid anchor which allows for assembly into the lipid bilayer of the liposome resulting 
in protrusion of the head group, which could possibly shield or block the positive 
charges of the liposome thus reducing availability of these positive charges and 
thereby interfering with the binding of the liposome to the siRNA.  Another possible 
reason for the observed disparity in targeted versus untargeted liposome binding 
efficiency could be that the incorporation of the β-galactose residue caused more of 




affording less positively charged cationic liposomes. Hence more of the liposome 
was required to bind the negatively charged siRNA.  
 
 
   












obtained from the retardation studies was utilized for optimising transfection studies 
of HepG2 cells in vitro (chapter four). Lipoplexes containing liposomes ranging from 
above to below optimum binding ratio (end points) were investigated.      
 
3.4.3 SYBR®Green Displacement Assay 
 
Traditionally, the dye displacement or intercalation assay demonstrates 
displacement of DNA-associated ethidium bromide by cationic liposomes (Geall et al., 
2000; Xu et al., 1996). Ethidium bromide is a cationic dye that intercalates between 
the base pairs of both double-stranded DNA and RNA. It exhibits weak fluorescence 
in solution, but upon ‘binding’ to nucleic acids it fluoresces strongly. It was Sorbell et 
al. (1977) who first proposed that ethidium bromide requires flexibility within the 
structure of the nucleic acid for intercalation. They also suggested that ethidium 
bromide exists in equilibrium between the intercalated sites on the nucleic acid and 
free in solution. Thus a loss of flexibility through DNA condensation would result in a 




(siRNA : Cationic liposome)  
(-ve : +ve) 
1. SD-CholTC 1 : 4.7 
2. SD-CholTT 1: 5.7 
3. SD-CholQC 1 : 5.1 




fluorescence (Geall et al., 2000). This premise has been extensively utilised to 
demonstrate cationic liposome induced DNA condensation and binding (Hsieh et al., 
1994; Xu et a.l, 1996; Singh et al., 2006).  
 
In this investigation the ethidium bromide intercalation assay was adapted for use 
with siRNA. SYBR®green ll nucleic acid dye was substituted for ethidium bromide. 
SYBR®green is also an intercalating dye from the cyanine family of dyes. The 
mechanism of action of this minor-groove binding dye has not been fully elucidated, 
however it does exhibit a higher quantum yield when bound to RNA compared with 
DNA and is significantly more sensitive than ethidium bromide i.e. it can detect as 
little as 500 pg RNA and exhibits several times greater affinity for RNA than does 
ethidium bromide.  In addition, it is non-mutagenic making it a safer alternative than 
ethidium bromide (Kirsanov et al., 2010; www.Lonza.com). For these reasons 
SYBR®green ll dye was used in the dye displacement assays. The results of the assay 
(Figure 3.4) revealed that all cationic liposome preparations were able to successfully 
displace SYBR®green from the control siRNA. This was demonstrated by a continuous 
decrease in SYBR®green fluorescence upon stepwise addition of the cationic 

































































Figure 3.4: The dye (SYBR green) displacement assay for cationic liposomes in 500 µl 
total reaction mixture containing 1.3 µg control siRNA and increasing amounts of 
liposome preparation (1 ml aliquots ≈ ± 3 µg). (a) SD-CholTC; (b) SD-CholTT; (c) SD-
CholQC and (d) SD-CholQT. (↓)Point of inflection. 
Varying amounts of cationic liposome (± 40 µg) were added to the reaction mixture 
for each preparation, until fluorescence measurements reached a constant value or 
plateau. The point at which this plateau occurred is referred to as the point of 
inflection and represents the siRNA : cationic liposome ratio at which maximum 
displacement of SYBR green or complete binding/condensation of siRNA occurred. 
Approximately 25 µg of SD-CholTC liposome was required to reach this point, 
equivalent to siRNA : liposome ratio of 1 : 19. SD-CholTT required 33.5 µg at a ratio 
of 1 : 26, SD-CholQC required 31 µg at a ratio of 1 : 24, while SD-CholQT needed 40 
µg at a ratio of 1 : 31. The siRNA : liposome ratios obtained for this assay seem to 
correlate well with those obtained for the gel retardation assay (Table 3.2). This 
would suggest that siRNA binding and compaction occurs at a similar point. The 
relatively small difference observed between the ratios could be attributed to one of 
two reasons, namely: the fact that the dye displacement assay is based on nucleic 
acid condensation while the gel retardation assay is based on charge neutralisation 
(i.e. the point at which the negative charges of the nucleic acid are completely 
titrated by the positive charges of the liposome), and the relatively high sensitivity of 






From the results obtained, it can be seen that both the SD-CholT and SD-CholQT 
liposomes exhibited a higher degree of siRNA compaction as compared with the SD-
CholQC liposome. SD-CholTC and SD-CholTT yielded a 78% and 80% reduction in 
fluorescence, respectively, while, SD-CholQC and SD-CholQT demonstrated a 
fluorescence decrease of 60% and 80%, respectively. This percentage of fluorescence 
reduction is said to correlate with the degree of nucleic acid condensation or 
compaction. Thus, although all four liposome preparations demonstrated siRNA 
condensation capabilities, three of the preparations demonstrated superior 
compaction ability. From the results obtained it can also be seen that the SD-CholT 
liposomes were able to displace SYBR®green more efficiently than the SD-CholQ 
liposomes. This is seen by the 23.5% average reduction in fluorescence observed 
after initial addition of the SD-CholT liposomes compared with the 7.5% average 
reduction observed after addition of the SD-CholQ liposomes. This supports the 
results obtained for the gel retardation studies which showed that greater quantities 
of the SD-CholQ liposomes were required to form complexes with the siRNA as 
compared with the SD-CholT liposomes. This difference in SYBR®green displacement 
could be attributed to steric hindrance of the larger trimethyl head group as 
opposed to the smaller dimethyl head group. Also noteworthy is the fact that the SD-
CholQC liposome demonstrated a slightly poorer ability to condense the siRNA when 
compared with its targeted counterpart. This is a somewhat surprising result, as one 
would theoretically expect the galactose residues on the SD-CholQT liposome to 
interfere with compaction due to shielding. A possible reason for this difference in 
condensation ability could be attributed to charge repulsion between the trimethyl 
amino head groups, which may affect SD-CholQC’s ability to condense siRNA. The 
presence of the galactose residues may reduce this charge repulsion, thus affording 
better compaction ability. Further study is required, perhaps x-ray diffraction to 
provide additional data on the nature and structure of the lipoplexes. In accordance 
with work done by Kunath et al. (2003), who showed that the incorporation of a 
targeting ligand affects nucleic acid binding, the findings of this assay also show that 
a greater amount of the SD-CholTT and SD-CholQT liposomes was required to reach 
the point of inflection. The results of this assay suggest that the presence of the 




quantity required to condense the siRNA. Once again, steric shielding could be a 
possible reason for the observed result. Martin et al. (2005) noted that head group 
size may cause steric repulsion between neighbouring head groups affecting 
binding/condensation ability.      
 
Overall, the results from this assay provide further evidence that the cationic 
liposomes described in chapter two are able to successfully bind the siRNA. It also 
provides preliminary proof that cationic liposomes are able to cause condensation or 






3.4.4 Nuclease Protection Assay 
 
Enzymatic degradation of nucleic acids is a major obstacle facing successful genetic 
therapeutics (Roa, 2010). Various nucleases found in blood serum attack siRNA 
resulting in its disintegration and inability to bring about a therapeutic effect (Zhang 
et al., 2006). Naked siRNA has been shown to be stable in serum for several minutes 
to about an hour, depending on serum concentration (Reischl and Zimmer, 2008).  In 
addition to nucleases, serum also contains a number of components such as lipids 
(eg. phospholipids), polysaccharides and proteins (e.g. albumin, lipoproteins, and 
macroglobulins) that could interfere with interaction between (i) lipoplex 
components and (ii) lipoplexes and cells (Rhinn et al., 2009; Ryhänen, 2006; Sato et 
al., 2007). Thus the effect of serum components on lipoplexes is of particular interest 
as inefficient protection of the nucleic acid or unstable complexes are adverse 
features of any delivery system (Oku et al., 2000). The protection or shielding ability 
afforded to siRNA by the cationic liposomes described in chapter two was 
determined by the nuclease protection assay. In addition, this assay allowed for the 





The results of the nuclease protection assay post-electrophoresis can be seen in 
Figure 3.5. Three concentrations of siTOX (25 nM, 50 nM and 100 nM) were 
examined. Lanes 1, 6 and 11 contained siTOX alone at the various concentrations, 
and were used as positive controls. Lanes 2, 7 and 12 contained siTOX (at the various 
concentrations) exposed to 10% FBS for four hours at 37°C. They served as the 
negative controls.  The remaining lanes (3-5, 8-10 and 13-15) contained lipoplexes 
after exposure to 10% FBS. Lipoplexes were composed of siTOX at 25 nM, 50 nM and 
100 nM and liposomes at below, optimum and above siRNA : cationic liposome 
optimum binding ratios as elucidated by gel retardation studies. From the result 
obtained, it can be seen that siTOX was completely degraded when subjected to the 
FBS. This was demonstrated by the lack of a band within the gel. From the results it 
can be deduced that all cationic liposomes afforded some degree of protection to 
the siTOX. Protection efficiency increased with an increase in siTOX concentration. 



















Figure 3.5: Nuclease protection assay of siTOX-cationic liposome complexes of (a) 
SD-CholTC, (b) SD-CholTT,  (c) SD-CholQC and (d) SD-CholQT in 13 µl reaction mixture 
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Lane 1, 6, 11: Naked siTOX at 25 nM, 50 nM and 100 nM concentrations,   
                respectively. 
Lane 2, 7, 12:  siTOX at 25 nM, 50 nM and 100 nM, respectively, with 10% FBS.   
 
(a) Lane 3-5: 25 nM siTOX with varying amounts of SD-CholTC (8, 9 and 10 µg) and 10% FBS.  
Lane 8–10: 50 nM siTOX with varying amounts of SD-CholTC (8, 9 and 10 µg) and 10% FBS. 
Lane 13–15: 100 nM siTOX with varying amounts of SD-CholTC (8, 9 and 10 µg) and 10% FBS. 
 
(b) Lane 3-5: 25 nM siTOX with varying amounts of SD-CholTT (11 , 12 and 13 µg) and 10% FBS. 
Lane 8–10: 50 nM siTOX with varying amounts of SD-CholTT (11, 12 and 13 µg) and 10% FBS. 
Lane 13–15: 100 nM siTOX with varying amounts of SD-CholTT (11, 12 and 13 µg) and 10% 
FBS. 
 
(c) Lane 3-5: 25 nM siTOX with varying amounts of SD-CholQC (10, 11 and 12 µg) and 10% FBS. 
Lane 8–10: 50 nM siTOX with varying amounts of SD-CholQC (10, 11 and 12 µg) and 10% FBS. 
Lane 13–15: 100 nM siTOX with varying amounts of SD-CholQC (10, 11 and 12 µg) and 10%    
FBS. 
 
(d) Lane 3-5: 25 nM siTOX with varying amounts of SD-CholQT (13, 14 and 15 µg) and 10% FBS. 
Lane 8–10: 50 nM siTOX with varying amounts of SD-CholQT (13, 14 and 15 µg) and 10% FBS. 
Lane 13–15: 100 nM siTOX with varying amounts of SD-CholQT (13, 14 and 15 µg) and 10%  
FBS. 
It was also observed that SD-CholT liposomes afforded slightly better protection to 
siTOX as compared with the SD-CholQ liposomes, suggesting that the complexes 
formed between the SD-CholQ liposomes and siTOX may be less stable than the SD-
CholT lipoplexes. It is also noteworthy that an increase in molar concentration 
resulted in an observed increase in protection efficiency. This is probably an 
erroneous conclusion and a more plausible explanation would be that an increase in 
siTOX concentration resulted in a subsequent increase in the amount of intact siTOX 
remaining after exposure to the FBS.   
 
The three concentrations of siTOX (25 nM, 50 nM and 100 nM) used were those 




and various siRNA manufacturers (including Dharmacon) have suggested 
investigating a range of siRNA concentrations for optimisation of transfection in 
different/specific cell lines (Yadava, 2004; www.dharmacon.com). Typically, siRNA 
concentrations ranging from 20 nM to 200 nM have been utilized for transfection of 
mammalian cells (Yadava, 2007). However, due to low transfection efficacy and non-
specific effects at the lower (<20 nM) and upper ranges (>100 nM), respectively (Oh 
et al., 2009; Persengiev et al., 2004; Yadava, 2007) concentration range of 25 nM to 
100 nM was chosen for investigation. For this assay, EDTA and SDS were added to 
reaction mixtures after nuclease digestion. EDTA is a chelating agent which was used 
to halt nuclease activity by removing necessary divalent ions from solution, while 
SDS, an anionic surfactant, was used to release the siTOX  RNA (nucleic acid) from 
the lipoplexes.       
 
Overall, the results of this assay demonstrated that all cationic liposome 
preparations provided some degree of protection against nuclease digestion to 
siTOX in the presence of 10% FBS for a period of four hours at 37°C. Increased siRNA 
concentration resulted in a greater amount of intact siRNA remaining after serum 




3.4.5 TEM of siRNA Lipoplexes 
 
Transmission electron microscopy (Figure 3.6) revealed a generally, heterogenous 
population size amongst the various siRNA lipoplexes examined. The majority of 
lipoplexes ranged, on average, from 300 nm to 600 nm in size. Visual examination of 
the various lipoplexes showed that the SD-CholT lipoplexes appeared as tightly 
compacted clusters or aggregates. In contrast, the SD-CholQ lipoplex micrographs 
showed very loosely bound structures. These findings support results obtained from 
the gel retardation, dye displacement and nuclease protection assays, which noted 
the difference in binding and compaction ability observed for the different cationic 




form less stable complexes with the siRNA. This may be a result of weak electrostatic 
interaction between the trimethyl head group of the SD-CholQ liposomes and the 
phosphodiester backbone of the siRNA. Dispersion in a dilute environment may have 
led to rapid disintegration of the lipoplexes as a result of this weak interaction. 
Please note that any artefacts seen in the TEM micrographs can be attributed to the 
cryoTEM process.         
 
Lipoplex size is a critical factor for transfection efficiency (Roa et al., 2010). 
Appropriate lipoplex size has not yet been clearly defined, with conflicting results 
from various studies creating ambiguity within the field. Ross et al. (1999) 
demonstrated that efficient transfection could be achieved with lipoplexes sized 
between 200 and 2000 nm, while Zhang et al. (2003) indicated lipoplexes smaller 
than 200 nm were more efficient transfectors of cells. An important parameter in 
determining the size of lipoplexes is the charge density of its components (Roa et al., 
2010). In accordance with this, all lipoplexes assembled were of a similar siRNA : 
cationic liposome charge ratio hence lipoplexes were of a similar size range, if not 























Figure 3.6: Transmission electron microscopy with negative staining, of the four 






In summary, this chapter has yielded information on the binding and condensation 
ability of the cationic liposomes described in chapter two. Successful siRNA : cationic 
liposome binding and elucidation of optimum binding ratios was demonstrated. 
Compaction or condensation of siRNA was also achieved. In addition, the ability of 






the results, it can be seen that the interaction between the Chol-Q containing 
liposomes and the siRNA was weak, as suggested by the band shift and nuclease 
protection assays. This apparent weak interaction is confirmed in the dye 
displacement assay, where the SD-CholQC liposome, in particular displaced less dye 
than the other three liposomes. Although the Chol-Q : siRNA interaction appears 
weaker than the Chol-T : siRNA association, this maybe a desirable feature in 
transfection studies as the siRNA cargo might be released more readily from the 
lipoplex. Overall, these findings demonstrate the interaction between the siRNA and 



























Transfection involves the non-viral introduction or ‘transfer’ of foreign genetic 
material into eukaryotic cells (Gopalakrishnan and Wolff, 2009). It is an important 
technique in cellular biology research allowing for the study of gene function and 
treatment of gene-related diseases (Gopalakrishnan and Wolff, 2009). There are a 
variety of physical or chemical methods that can be employed for the introduction of 
nucleic acids into recipient cells (Hodgson, 1995). Some earlier transfection methods 
involved the use of electroporation, micro-injection, particle bombardment and 
complexation of nucleic acid to calcium phosphate or diethylaminoethyl (DEAE) 
dextran (Sambrook and Russel, 2001; Szelei and Duda, 1989). Liposome-mediated 
gene transfer offered a promising alternative to other transfection methods that 
proved either unsafe or unsuitable, especially for in vivo gene delivery. However, 
invariable entrapment/binding and transfection efficiencies and high toxicity meant 
that conventional and cationic liposomes did not initially gain widespread use as 
gene delivery vectors. It wasn’t until Felgner and co-workers, in 1987 synthesized the 
monovalent cationic lipid N-[1-(2,3-dioleoyl) propyl-N,N,N-trimethylammonium 
chloride] (DOTMA), that cationic liposome-mediated transfection gained support 
(Felgner et al., 1987; Lasic, 1997; Szelei and Duda, 1989).  
 
Gene transfer can be conducted in vitro or in vivo. In vitro gene delivery (DNA and 
RNA) has achieved much success using a diverse range of vectors including cationic 
liposomes. However, in vivo transfection with cationic liposomes has met with 
limited success due to problems associated with binding to polyanionic glycans or 
proteins present in the extracellular matrix, rapid elimination by the 
reticuloendothelial system, instability in serum and serum-associated degradation of 
nucleic acid (Gad, 2007; Zanta et al., 1997). Traditionally, two basic types of 
transfection can occur, namely: (i) transient, and, (ii) stable transfection. Transient 
transfection refers to the introduction of foreign nucleic acids into a cell without 
change to the chromosomal DNA, while stable transfection refers to the 
incorporation of foreign DNA into the cell genome. Expression efficiency is generally 
an order of magnitude higher in transient transfections as compared with stable 
transfections (Sambrook and Russel, 2001). The use of synthetic siRNA in 




transfection experiments should include positive and negative controls to compare 
or test the validity of results.  An important consideration in transfection efficiency is 
the selection of cell line to be used. It has been demonstrated that a transfection 
agent that works well in one type of cell may be ineffective in another cell line 
(Sambrook and Russel, 2001).   
 
The cationic lipoplex system has formed the basis for development of numerous 
ligand-targeted gene delivery systems over the years. Emerging studies have shown 
the adaptation of these systems for siRNA delivery (Huang et al., 2005). In this 
investigation, we designed and developed a synthetic siRNA transfer system based 
on cationic liposome-mediated transfection that could be targeted to a specific cell 
type. The cell line chosen for specific targeting was the HepG2 cell line, one of two 
human cell lines that were isolated from liver biopsies of hepatocellular carcinomas 
and hepatoblastomas (Aden et al., 1979), which exhibit the same capabilities of 
normal liver parenchymal cells (Knowles et al., 1980). Targeting was achieved by 
incorporation of galactose-terminating residues into the cationic liposome structure 
during synthesis. The targeted siRNA delivery system was subsequently prepared by 
incubation of the various cationic liposome preparations (SD-CholTC, SD-CholTT, SD-
CholQC and SD-CholQT) with the control siRNA or the siTOX molecules.  
     
Hepatocytes are attractive targets for gene delivery as they produce a large number 
of serum proteins (such as albumin, transferrin, fibrinogen, ceruloplasmin and α-
fetoprotein), allowing for study and treatment of a wide range of genetic defects. In 
addition, hepatocytes contain a number of receptors that can be targeted for gene 
delivery, including the asialoglycoprotein (ASGP) receptor. Also referred to as the 
hepatic lectin, this 41 kD transmembrane heteroligomer glycoprotein composed of 
two subunits, H1 and H2 in human hepatocytes, is predominantly expressed on the 
sinusoidal surface and is responsible for the clearance of glycoproteins with 
desialylated acetylglucosamine or galactose residues from circulation via receptor-
mediated endocytosis (Wu et al., 2002). ASGP receptor recognition and 
internalization is both highly specific and rapid, making it an extremely effective 




proposed receptor-ligand recognition of β-D-galactopyranoside containing siRNA 





Figure 4.1: An illustration of the interaction between the galactose-containing siRNA 
lipoplexes and the HepG2 cell where: represents the siRNA molecule and    
       represents the (β)-D-galatopyranoside residue (Diagram not drawn to scale).  
 
 
siRNA knockdown can be achieved and assessed using a variety of methods, such as: 
reporter genes, visual inspection, conventional viability assays and assaying mRNA 
(example: Real time-PCR) or protein levels (example: western blot analysis), 
depending on the siRNA source being utilized (refer to chapter 1) i.e. DNA-based 
RNAi or synthetic siRNAs (www.promega.com). Like most DNA or plasmid 
transfections, there are numerous factors that can affect efficiency of siRNA delivery 
into mammalian cells in vitro. These include: lipoplex formation, particle size, surface 
charge, cell density, incubation and assay time and siRNA concentration (Kim et al., 
2010; Vestin et al., 2008; www.dharmacon.com). Hence transfection conditions 
require optimization to obtain the best knockdown of gene expression (Engelke and 

































siGenome non-targeting siRNA (control siRNA) and siCONTROL TOX siRNA (siTOX) 
were purchased from Thermo Sciencific Dharmacon, Lafayette, CO. HEK293 cells, 
HepG2 cells and irradiated foetal bovine serum (FBS) were obtained from Highveld 
Biological (PTY) Ltd., Lyndhurst, South Africa. Minimum Essential Medium (MEM) 
containing Earle’s salt and L-glutamine, trypsin/versene and penicillin/streptomycin 
(5000 units penicillin/5000 µg streptomycin/ml) were purchased from Lonza 
BioWhittaker, Walkersville, USA. The Cell Titre 96® aqueous one solution cell 
proliferation assay kit was obtained from the Promega Corporation, Madison, USA. 
All tissue culture plastic consumables were purchased from Corning Incorporated, 





4.3.1 Maintenance of HEK293 and HepG2 Cells  
 
4.3.1.1 Preparation of Culture Medium 
 
MEM powder was dissolved in 900 ml of 18 Mohm water. Thereafter, 10 mM 
NaHCO3, 20 mM HEPES and 5 000 units (10 ml) penicillin/streptomycin antibiotic was 
added to the medium and the pH of the solution was adjusted to between 7.3 and 
7.4. The medium was then made-up to 1 litre with 18 Mohm water and subsequently 
filter sterilized using a Millipore 0.22 µm bell filter and Cole-Palmer Masterflex 
(7017-12) peristaltic pump. The sterilized MEM was aliquoted into 250 ml autoclaved 
Schott bottles and left for 24 hours at room temperature (23-25°C) to assess sterility. 
The MEM was subsequently stored at 4°C. Prior to use, the MEM was warmed to 
37°C in a water bath and supplemented with 10% FBS (complete medium).        
 





A vial of cryopreserved HEK293 or HepG2 cells was removed from the biofreezer      
(-80°C) and placed in a 37°C water bath to thaw (± 2 minutes). The vial was 
subsequently removed from the water bath and subjected to centrifugation at 1000 
rpm for 3-5 minutes to pellet cells. The vial was then wiped with ethanol and opened 
aseptically in a laminar flow cabinet. The supernatant was discarded and the cell 
pellet was resuspended in 1 ml of fresh complete medium (MEM with 10% FBS). This 
cell suspension was vortexed and then transferred to a cell culture flask containing 5 
ml complete medium. The flask containing the cells was placed in a 37°C incubator. 
Cells were visualized using a Nikon TMS light microscope.  Medium was changed 
every two to three days when cells were at or near confluency.        
 
4.3.1.3 Propagation of Cells 
 
Cells near or at confluency were subjected to trypsinisation. This process involved 
discarding spent medium from the culture flask into a sterile waste bottle and then 
washing cells with 5 ml sterile phosphate buffered saline (PBS) (150 mM NaCl, 2.7 
mM KCl, 1 mM KH2PO4, 6 mM Na2HPO4; pH 7.5). Thereafter 1 ml of trypsin/versene 
solution was added to the cells. Trypsinisation was allowed to proceed for 
approximately 5 minutes at room temperature and observed with a Nikon TMS light 
microscope. Subsequently, 2 ml of complete medium (MEM with 10% FBS) was 
added to the flask and then trypsinised cells were dislodged from the inner flask 
surface by firmly tapping the flask against the palm. The resultant cell suspension 
was split at a desired ratio (eg. 1 : 3) into flasks containing 5 ml complete medium 
each. Flasks were then incubated at 37°C and medium was changed when necessary. 
Confluent cells were either re-trypsinised or cryopreserved when neccessary.     
 
 
4.3.1.4 Cyropresevation of Cells 
 
Confluent or semi-confluent cells were trypsinised as outlined in 4.3.1.3. The cell 
suspension was then subjected to centrifugation at 1000 rpm for 3 – 5 minutes. The 




complete medium (MEM with 10% FBS) and 0.1 ml dimethoxysulfoxide (DMSO). The 
cell suspension was vortexed and then aliquoted into cryogenic vials which were 
vacuum sealed in plastic jackets and frozen at a drop rate of 1°C per minute to -50°C 
using a cold probe. The frozen cells were then stored in a NUAIRE biofreezer at -80°C.  
 
4.3.2 Preparation of siRNA Lipoplexes 
 
Varying amounts of cationic liposome were added to various concentrations of 
either control siRNA or siTOX (25 nm, 50 nm and 100 nm) at ratios set out in Table 
4.1. Lipoplex reaction mixtures were then made up to a final volume of 13 µl with 
HBS. Complexes were allowed to incubate at room temperature (25⁰C) for a 
minimum of 30 minutes prior to introduction into cells.     
 
 




Liposome Preparation siRNA :Liposome ratio 
(w/w) * 
1. SD-CholTC 1 : 16 1 : 18 1 : 20 
2. SD-CholTT 1 : 22 1 : 24 1 : 26 
3. SD-CholQC 1 : 20 1 : 22 1 : 24 
4. SD-CholQT 1 : 26 1 : 28  1 : 30 
 
 
*End-point ratio as determined by gel retardation assay 
4.3.3 Growth Inhibition Studies 
 
HEK293 or HepG2 cells at or near confluency were trypsinised and seeded evenly 
into 48-well plates at a seeding density of approximately 2.8 x 106 cells/unit volume 




hours to allow for cell adherence. siRNA lipoplexes containing control siRNA were 
prepared as described in 4.3.1. Cells were prepared by first removing spent medium 
and replacing with 0.25 ml of serum-free medium (MEM without 10% FBS). The 
siRNA lipoplexes were then added to the wells containing the cells. Control wells 
containing cells alone, cells with siRNA at the 3 weight ratios and liposome alone at 
optimum binding amount were also set-up. The assays were carried out in triplicate. 
Cells were then incubated for 4 hours at 37°C, after which the medium was 
replenished with complete medium. The cells were then incubated for a further 48 
hours at 37°C. After the 48 hour incubation period, 50 µl of Cell Titre 96® aqueous 
one solution cell proliferation reagent was added to all wells. Cells were then 
incubated for 4 hours at 37°C. A blank sample containing complete medium and the 
cell proliferation reagent was also prepared. Absorbance values for all samples were 
read on a Thermo Electron Corporation Biomate 3 UV/visible spectrophotometer at 
a wavelength of 490 nm.           
 
4.3.4 Transfection Studies 
 
siRNA lipoplexes containing siTOX at three concentrations were prepared as outlined 
in 4.3.1. As in 4.3.3, HEK293 or HepG2 cells near or at confluency were trypsinised 
and seeded evenly into 48-well plates at a seeding density of approximately 2.8 x 106 
cells/unit volume. Cells were then incubated at 37°C for 24 hours, prior to medium 
change and introduction of siRNA lipoplexes into wells. After a 4 hour incubation at 
37°C, serum-free medium was replaced with complete medium (MEM with 10% FBS) 
and cells were incubated for a further 48 hours at 37°C.  Following incubation, 50 µl 
of Cell Titre 96® aqueous one solution cell proliferation reagent was added to all 
wells. Cells were then incubated for 4 hours at 37°C. Absorbance values for all 
samples were then read as in 4.3.3. 
4.4 Results and Discussion 
 





The HEK293 and HepG2 cells (Figure 4.2a and b, respectively) were successfully 
reconstituted, maintained and propagated during the course of this investigation. 
HEK293 cells are derived from human embryonic kidney cells. The cell line was 
initiated by transformation of HEK cells with sheared adenovirus 5 DNA. Some of the 
receptors expressed on this cell include: corticotrophin, muscarinic acetylcholine, 
sphingosine-1-phosphate and transient potential receptors, but not the ASGP 
receptor (www.hek293.com). As previously mentioned, HepG2 is a liver cell line 
derived from human hepatoblastoma (Javitt, 1990). It expresses the 
asialoglycoprotein (ASGP) receptor on the extracellular surface of the plasma 
membrane, which recognizes and binds ligands with terminal D-glucose or galactose 
residues (Watanabe et al., 2007). A single HepG2 cell contains approximately 
225 000 ASGP receptors, with 80% located on the plasma membrane (Schwartz et al., 
1982). Thus the HEK293 cells which do not express the ASGP-R were utilized as the 
receptor negative cell line and the HepG2 cells were the receptor positive cell line in 
our investigation.  
 
 
Viability of cells post-cryopreservation was assessed by reconstituting 1 vial of a 
batch of frozen cells every 3-4 weeks. Successful reconstitution and growth of frozen 
cells was used as an indicator of successful cryopresevation. Both the HEK293 and 
HepG2 cells were grown in minimium essential medium (MEM) with 10% foetal 
bovine serum. The cells demonstrated a slight difference in growth pattern, as the 
HEK293 cells attached and multiplied at an initial rate that was faster than that of 
the HepG2 cells. The HepG2 cells initially exhibited slow growth. This is an observed 
characteristic of HepG2 cells after a prolonged period of cryopreservation. The 
HEK293 cells reached confluency 3 to 4 days after reconstitution and required 
trypsinization. The HepG2 cells reached confluency 4 to 5 days following 
reconstitution and subsequently required trypsinization every 2 to 3 days. The 
increase in HepG2 growth rate can be attributed to the increase in growth factors 
present in the medium over a period of time, a direct result of increased cell growth. 




once settled they grew at a faster rate than the HEK293 cells which maintained a 
relatively constant growth rate during the study period.     
    
 




Figure 4.2: Monolayer of (a) HEK293 cells and (b) HepG2 cells at semi-confluency 
viewed with an Olympus microscope (at 10x and 20x magnification, repectively). 
   
 
 
4.4.2 siRNA Lipoplex Formation 
 
siRNA/siTOX lipoplexes were successfully prepared as demonstrated by cryoTEM, gel 
retardation, serum nuclease assay (chapter three) and transfection studies (4.3.4). A 
30 minute incubation of the siRNA/siTOX with the various cationic liposome 
preparations (SD-CholTC, SD-CholTT, SD-CholQC and SD-CholQT) was sufficient to 
form the lipoplexes.  As previously mentioned (3.4.1), the control siRNA was 
employed to monitor non sequence-specific toxicity, while siTOX was used for 











All cationic liposome preparations exhibited low toxicity and were well tolerated by 
both the HEK293 and HepG2 cells, as shown in Figures 4.4 and 4.5, respectively.  
 
Cytotoxicity is an important factor in non-viral gene therapy that is often ignored.   
(Liu, 2006). Naked siRNA is essentially inert when administered, however when 
complexed to cationic lipids it has been shown to induce an interferon response 
(type l and ll) and STAT 1 activation (Ma et al., 2005). First generation cationic lipids 
were largely toxic to most insect and mammalian cells. Later generations, although 
considerably less toxic than their predecessors have been shown to reduce cell 
viability at higher doses (Sambrook and Russel, 2001; Zhdanov et al., 2001). Cationic 
lipids and liposomes can cause two types of toxicity in biological systems that can 
result in apoptosis of cells, namely: (i) aggregation, flocculation and thrombosis of 
blood components and (ii) solubilization, hemolysis and poration of the plasma 
membrane (Lasic, 1997). Cell shrinking, vacuolization of the cytoplasm, creation of 
transmembrane pores and reduction in mitoses cycles have been observed as toxic 
effects of cationic lipids (Lappalainen et al., 1994; Lasic, 1997). Lipoplex cytotoxicity 
has been attributed to cationic lipids binding to intracellular anionic lipids with a 
resultant compromise of cellular metabolic pathways (De Rosa et al., 2009). Cationic 
lipid toxicity is generally closely associated with the charge ratio between nucleic 
acid and liposome, dose of lipoplex and number of positive charges on the lipid (Dass, 
2002; Lasic, 1997).  
 
Toxicity of drugs and delivery vectors can be determined by performing thrombosis, 
hemolysis and cytotoxicity assays (Lasic, 1997). In our investigation we utilized the 
Cell Titre 96® aqueous one solution cell proliferation assay containing the [3-(4,5-
dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt] (MTS) reagent, which is bioreduced by viable cells into a coloured 
formazan product (Figure 4.3) that is soluble in tissue culture medium. The quantity 
of formazan produced is directly proportional to the number of living cells as 
measured by the absorbance at 490 nm (www.promega.com). Thus cytotoxicity and 
transfection efficiencies were determined by comparing cell survival rates after cell 








Figure 4.3: Structure of MTS tetrazolium reagent and its bioreduced formazan 
product (www.promega.com or Promega Technical Manual- Cell Titre 96® aqueous 
one solution cell proliferation assay). 
 
From results presented in Figures 4.4 and 4.5 it can be seen that all lipoplexes were 
well tolerated by the HEK293 and HepG2 cells at the various siRNA concentrations 
and siRNA : cationic liposome ratios tested.  Control siRNA was used in this assay to 
determine sequence independent cytotoxicity of functional siRNA (i.e. siTOX). There 
were five controls set up, i.e. untreated cells, liposome treated cells (amount at 
optimum binding ratio), and siRNA treated cells at three concentrations (25 nM, 50 
nM and 100 nM). On average, the HEK293 cells observed an 88% cell survival when 
exposed to the four liposomes formulations. The HepG2 cells also observed a high 
average cell survival rate of 87%. The low toxicity observed is in accordance with 
studies by Wen et al. (2004), who also observed that a DC-Chol/DOPE galactosylated 
liposome exhibited low toxicity in HepG2 cells in vitro. There was little or no 
appreciable difference in cell mortality rates observed between the non-targeted 
and the targeted liposomes. This is also in agreement with the work performed by 
Wen et al. (2004). An average maximum growth inhibition of 18% in HEK293 cells 
(Figure 4.4 c) and 21% in HepG2 cells (Figure 4.5 c) was observed for the SD-Chol QC 
liposome at a siRNA : liposome ratio of 1 : 22 and 1 : 24, respectively, complexed to 













































Figure 4.4: Growth inhibition studies of cationic liposomes in HEK293 cells in vitro. 
Control siRNA at 25 nM, 50 nM and 100 nM concentrations were complexed to 
cationic liposomes at varying ratios. (a) SD-CholTC, (b) SD-CholTT, (c) SD-CholQC and 
(d) SD-CholQT. Data is represented as a means ±SD (n=3).   
 (c) 



































  (b) 



































Figure 4.5: Growth inhibition studies of cationic liposomes in HepG2 cells in vitro. 
Control siRNA at 25 nM, 50 nM and 100 nM concentrations were complexed to 
cationic liposomes at varying ratios. (a) SD-CholTC, (b) SD-CholTT, (c) SD-CholQC and 
(d) SD-CholQT. Data is represented as a means ±SD (n=3).   
  (d) 




























It is also interesting to note that the cationic liposomes containing the Chol-Q 
derivative exhibited a slightly higher cell mortality rate as compared with their Chol-
T counterparts. This result is in agreement with studies by Bottega and Epand (1992), 
who showed that a quaternary ammonium head group was more toxic than a 
tertiary head group. An increase in liposome quantity did not result in a decrease in 
cell viability, suggesting that even at higher doses the cationic liposomes proved 
relatively non-toxic to the cells. A possible contributing factor to the observed low 
toxicity of the cationic liposomes could be attributed to their carbamoyl linker bond. 
Biodegradable bonds such as ester and carbomoyl are reported to be less cytotxic 
than more stable bonds (Huang, 1999). Galactosylation has also been shown to 
reduce membrane damaging effects typical of polycations, by affecting electrostatic 
interaction between cationic complexes and anionic cell surfaces (Kunuth et al., 
2003). IC50 (i.e. 50% cell mortality) was not seen for any of the liposome preparations 
at the tested ratios.  
 
Toxicity studies are important determinants of the safety and thus viability of non-
viral gene delivery vectors for future in vivo studies. The results of the growth 
inhibition assay demonstrated the relative lack of toxicity of the cationic liposomes 




4.4.4 Transfection Studies 
 
All cationic liposome preparations (SD-CholTC, SD-CholTT, SD-CholQC and SD-CholQT) 
demonstrated varying degrees of transfection activity as assessed by the MTS cell 
proliferation assay (Figures 4.6 and 4.7). 
 
Transfection experiments were performed on HepG2 hepatocytes expressing the 
asialoglycoprotein receptor and on HEK293 embryonic kidney cells lacking this 
receptor. siRNA lipoplex transfection efficiency was evaluated by the MTS assay 




previously mentioned, Dharmacon’s siTOX is toxic only when delivered to cells, with 
apoptosis and cell death observed within 24 – 48 hours post successful transfection. 
For transfection studies five controls were set up as per the cell inhibition assay. In 
our investigation we were unable to test mRNA down-regulation as the target mRNA 
was not known, however siTOX is an effective system for measurement of 
transfection efficacy and suitable controls (listed above, section 4.3.3) were included 
in transfection studies to demonstrate that a decrease in cell viability was due to 
successful transfection of cells by the siRNA lipoplexes. Transfection efficiency was 
expressed as a ‘percentage cell viability’ with respect to the cells alone control 
(100%). Yadava (2007) used a similar approach in siRNA knockdown experiments. 
Significance values (p) were calculated using the two tailed student's t-test for the 
comparison of two groups. Transfection experiments were performed in the absence 
of serum as it is believed that polyvalent negatively charged molecules present in 
serum may compete in charge interaction or coat complexes with serum 
components, thus hindering and reducing cellular uptake (Harrison et al., 1995; 
Madeira et al., 2008; Zhang et al., 2010).  
 
From the results obtained it can be seen that the cells exposed to the controls 
demonstrated a higher cell survival than those exposed to the siTOX lipoplexes. Thus 
the increased cell mortality rates could be attributed to successful transfection by 
the cationic liposomes. The 100 nM siTOX alone demonstrated the best knockdown 
capability as compared with its 20 and 50 nM counterparts. However this 
transfection/knockdown rate was significantly lower compared with siRNA lipoplex 
knockdown levels. It was also observed that, on average, the siRNA lipoplexes 
demonstrated an increased ability (11%) to transfect the HepG2 cells as compared 
with the HEK293 cells. Transfection using the targeted liposomes demonstrated the 
highest cell knockdown in both the HEK293 (18%) and HepG2 cells (33%), although 
transfection efficacy was higher in the HepG2 cells. Transfection of HepG2 cells using 
the two untargeted liposomes, SD-CholTC and SD-CholQC, demonstrated the lowest 
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Figure 4.6: Transfection studies of cationic liposomes in HEK293 cells in vitro. siTOX 
at 25 nM, 50 nM and 100 nM concentrations were complexed to cationic liposomes 
at varying ratios. (a) SD-CholTC, (b) SD-CholTT, (c) SD-CholQC and (d) SD-CholQT. 
Data is represented as a means ±SD (n=3).   
  (c) 
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Figure 4.7: Transfection studies of cationic liposomes in HepG2 cells in vitro. siTOX at 
25 nM, 50 nM and 100 nM concentrations were complexed to cationic liposomes at 
varying ratios. (a) SD-CholTC, (b) SD-CholTT, (c) SD-CholQC and (d) SD-CholQT. Data 
is represented as a means ±SD (n=3).   
  (c) 




























SD-CholTC (Figure 4.7 a) recorded the best transfection result, a 27% decrease in cell 
survival in the HepG2 cells with the 50 nM siTOX at a siTOX : liposome ratio of 1 : 16. 
SD-CholTT (Figure 4.7 b), a 57% reduction in HepG2 cells with the same molar 
concentration of siTOX at a siTOX : liposome ratio of 1 : 22. A 37% decrease in HepG2 
cells at a ratio of 1 : 22  was observed for the SD-CholQC (Figure 4.7 c) preparation at 
a siTOX concentration of 50 nM.  The SD-CholQT liposome (Figure 4.7 d) 
demonstrated superior transfection ability, showing a 70% reduction in HepG2 cells 
with 50 nM siTOX at a ratio of 1 : 26.  
 
From the results (Figure 4.8) it can be deduced that the increase in transfection 
efficiency observed for the targeted liposomes can be attributed to recognition and 
uptake by the ASGP receptor of the HepG2 cells. Moreover, overall transfection 
efficiencies achieved by all four siTOX lipoplexes in the receptor negative HEK293 
cells were low (± 22%). An alternate experiment referred to as a competition assay 
may also be performed to demonstrate that receptor-mediated endocytosis 
enhances cellular uptake of lipoplexes. The basic premise of this assay is that a 
decrease in liposomal cellular uptake in the presence of increasing amounts of free 
galactose demonstrates the effectiveness of receptor targeting (Kunuth et al., 2003). 
ASGP receptors are known to exhibit higher affinity for the galactopyranosyl moiety 
with specific interaction (in part) between the sugar’s 3-OH and 4-OH groups and 
specific carboxylate and amide groups of the receptor, with an equatorial 3-OH and 
axial 4-OH conformation nessessary for binding (Meier et al., 2000). Lee (1982) 
demonstrated that the equatorial 4-OH (as found in glucose) displays a weaker 
binding interaction than the axial 4-OH (as found in galactose). Additionally, previous 
work performed in our laboratory demonstrated increased transfection efficiency for 
the beta (β) versus alpha (α) conformation of the galactose residue. This suggests 
that the ASGP receptor was able to discern the C-4 epimeric and anomeric features 
for the hexose in direct glycosidic link to the cholesterol anchor (Singh et al., 2007). 






From the results, an observed trend showed that transfection efficiency is optimal 
using an siRNA : liposome ratio below optimum binding (as determined by gel 
retardation studies, chapter 3), as three of the four lipoplexes gave their highest cell 
knockdown rates at that particular ratio. From the results, it can also be seen that 
the 50 nM concentration of the siTOX demonstrated superior overall knockdown of 
cell viability when complexed to the cationic liposome as compared with transfection 
using the 20 nM and 100 nM siTOX lipoplexes.  A similar result was obtained by 
Cardosa et al. (2008) who observed that an siRNA concentration of 50 nM was ideal 
for efficient (±50%) gene knockdown in neuronal cells with low toxicity and low non-
specific effects as compared with 100 nM siRNA transfection.  It is somewhat 
surprising to note that the 100 nM siTOX demonstrated the poorest overall 
knockdown ability when complexed to the cationic liposomes.  A possible 
explanation for the observed result could be that an overly strong siRNA-cationic 
liposome interaction may prevent spatially appropriate release of the siRNA into the 
cytoplasm. Another possible reason could be that at the higher concentration, the 
siRNA ‘competes’ with itself to bind to the positive charges on the liposome, hence 
insufficient siRNA is bound to the liposome resulting in low transfection rates. 
Further study is required in this area. 
   
The overall results (Figure 4.9) showed that the targeted SD-CholQ liposomes were 
more effective transfectors of the HepG2 cell as compared with the targeted SD-
CholT liposomes with a 75% and 58% cell knockdown, respectively. This increased 
transfection efficiency could be attributed to the weaker binding interaction 
observed for SD-CholQ liposomes during electrophoretic gel analysis and 
SYBR®green displacement studies (chapter three). This weaker binding could have 
resulted in an easier disassembly of siRNA lipoplexes and release of siTOX into the 
cytoplasm for knockdown of target mRNA. This is in agreement with studies 
performed by Harvie et al. (1998) who demonstrated that weak binding interactions 
promoted disassembly of DNA from phosphatidylethanolamine containing lipid-









                    
 
 
Figure 4.8: Summary of optimum transfection results of control versus targeted 
lipoplexes at the various siTOX concentrations: (a) Chol-T and (b) Chol-Q. Data is 
represented as a mean ±SD (n=3). Key: (N.S.) Not significant, (*) p<0.002, (**) 








Figure 4.9: Summary of optimum transfection results with 50 nM siTOX complexed 
to: (a) SD-CholTC (1 : 16), (b) SD-CholTT (1 : 22), (c) SD-CholQC (1 : 22) and (d) SD-
CholQT (1 : 26). Data is represented as a mean ±SD (n=3). Key: (*) p<0.05, (**) 
p<0.001.   
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As previously mentioned, there are a variety of factors that can affect transfection 
efficiency. Three such factors are (i) cell density, (ii) assaying time and (iii) lipoplex 
size. (i) It has been established that low cell density may adversely affect cell 
recovery after transfection, while a too high cell density may inhibit cell growth and 
metabolism, reducing transfection rates (Dalby et al., 2004).  Although results 
obtained in this study demonstrated efficient knockdown of the HepG2 cells, 
especially for the targeted liposomes, overall knockdown could be improved.  Thus 
the 2.8 x 106 cells/unit volume employed during this transfection study may have 
been too high for optimum transfection of the HepG2 cells by the cationic liposome 
described in chapter two; (ii) Assay results are generally assessed 24 to 48 hours 
following lipoplex treatment (Dalby et al., 2004). Kim et al. (2010) observed that 
treatment of Cos7 (African green monkey fibroblasts) cells with arginine/siRNA 
complexes gave maximum inhibition of luciferase activity after 24 hours with a 
return to normal luciferase levels after 48 hours. The manufacturer of the control 
siRNA and siTOX, Dharmacon, suggested a guideline assaying time of between 24 to 
72 hours after treatment with the delivery system (siRNA technical handbook), and 
(iii) The effect of lipoplex size on transfection efficiency remains ambiguous. siRNA 
lipoplexes or complexes ranging in size from 60 nm to 600 nm have displayed 
efficient transfection ability with little or no difference observed between the 
smaller and larger aggregates (Spagnou et al., 2004). However, lipoplex size is still a 
consideration for efficient transfection. Hence further study exploring optimization 
of these parameters may lead to improvement in transfection activity.    
 
In summary, the results of the transfections studies demonstrated the superior 
transfecting ability of the targeted lipoplexes to HepG2 cells in vitro. The SD-CholQ 
liposomes demonstrated a better overall transfection efficacy as compared with the 
SD-CholT liposomes. It was also ascertained that an siRNA : cationic liposome ratio 
below optimum binding combined with a 50 nM concentration of siTOX proved most 








The potent and specific ability of siRNAs to bind to and promote degradation of 
target mRNAs through the endogenous biological pathway, RNAi, has immense 
therapeutic potential as an approach for treatment of a variety of diseases arising 
from aberrant protein expression (Leung, 2005; Takahashi et al., 2009). The 
efficiency of RNAi technology as a therapeutic modality hinges on a number of 
factors, however the crucial challenge for successful transition into clinics remains 
the issue of delivery (Shrey et al., 2007; Sioud, 2004; Takahashi et al., 2009). 
Amongst the carriers available for siRNA delivery, cationic liposomes have emerged 
as an attractive option owing to their versatility, relatively low toxicity and ability for 
cell-specific targeting. In the case of the latter, the coupling of liposomes with ligands 
which bind to cognate receptors on the surface of targeted cells is one of the most 
promising avenues for cell-specific drug and gene delivery.  The ASGP receptor found 
on mammalian hepatocytes preferentially binds to glycoproteins that possess 
carbohydrate chains terminating in glucose or galactose residues, providing a unique 
means for the development of liver-specific siRNA delivery systems (Torchilin et al., 
1988; Wu et al., 2002). Hashida et al. (2005) incorporated ligands with terminal 
galactose residues into liposomal membranes and succeeded in increasing liposomal 
accumulation in the liver. Although numerous cationic lipids (formulated into 
liposomes) commonly used for conventional DNA transfection have been employed 
for siRNA transport, an apparent need still exists for development of new cationic 
lipids for improved siRNA delivery (Desigaux et al., 2007).       
    
In this investigation, novel hepatotrophic liposomes containing the cytofectins Chol-T 
or Chol-Q, and DOPE with and without cholesteryl-β-D-galactopyranoside were 
prepared by the thin film hydration technique. These cationic liposomes proved 
simple and quick to prepare. The liposomes were subsequently characterised by 
cryoTEM, revealing a relatively uniform size range of 80-150 nm and the presence of 




displacement studies demonstrated the ability of the liposomes to form lipoplexes 
with the synthetic siRNA at a negative (-ve) : positive (+ve) charge ratio of 1 : 5 to  
1 : 6.  Characterisation by cryoTEM revealed the relatively homogeneous nature of 
the siRNA lipoplex clusters at end-point ratios with a size range of ±500 nm.  The 
ability of the liposomes to condense siRNA was also demonstrated in the dye 
displacement study. Moreover liposomes were shown to offer siRNA a degree of 
protection from serum nuclease digestion. Growth inhibition studies demonstrated 
that all siRNA lipoplexes exhibited low to moderate toxicity in the concentration 
range selected for transfection studies in HEK293 and HepG2 cells in vitro. 
Transfection studies then revealed that the targeted SD-CholQ liposomes achieved 
superior cellular knockdown (75%) compared with the targeted SD-CholT liposomes 
(58%). These studies also clearly showed that the galactosylated cationic liposomes 
promoted cell knockdown almost an order of magnitude greater than the non-
galactosylated controls. Highest transfection activity was achieved by the SD-CholQT 
liposome complexed to siTOX at the 50 nM level. Transfection efficiency was shown 
to increase with lipoplexes at a binding ratio below optimum. This was a trend 
observed for most of the liposome preparations tested.  
 
The findings of this study suggest that the galactosylated liposomes, SD-CholTT and 
SD-CholQT are highly promising and potentially viable vehicles for the delivery of 
siRNA to hepatocytes. The siRNA lipoplexes should be further evaluated with the aim 
of ultimately achieving in vivo application. Further study should concentrate on 
optimization of parameters influencing transfection efficiency, such as cell density, 
lipoplex size and galactose density. Specific gene knockdown of a known mRNA 
target sequence should also be undertaken. Liposomal formulation development is a 
major focus of RNAi delivery. This rapidly evolving and exciting field of research is 
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Figure 1: 1H NMR spectra of 3β [N-(N’,N’-dimethylaminopropane)- carbamoyl] 
cholesterol (Chol-T). 
 
Figure 2: 1H NMR spectra of3β [N-(N’,N’,N’-trimethylammonium propane iodide)- 
carbamoyl] cholesterol (Chol-Q). 
 
 
156
APPENDIX B 
 
 
 
 
 
 
 
 
157
 
 
 
 
 
 
 
 
158
 
 
 
 
 
 
 
 
159
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
